

MORBIDITY AND MORTALITY

WEEKLY REPORT

- 701 Outbreaks of Multidrug-Resistant Salmonella Typhimurium Associated With Veterinary Facilities — Idaho, Minnesota, and Washington, 1999
- 704 Tularemia Oklahoma, 2000
- 707 Outbreak of Pneumococcal Pneumonia Among Unvaccinated Residents of a Nursing Home — New Jersey, April 2001
- **710** Adverse Events and Deaths Associated With Laboratory Errors at a Hospital Pennsylvania, 2001
- 712 Notice to Readers

Outbreaks of Multidrug-Resistant *Salmonella* Typhimurium Associated With Veterinary Facilities — Idaho, Minnesota, and Washington, 1999

CDC received reports in 1999 from three state health departments of outbreaks of multidrug-resistant *Salmonella* serotype Typhimurium infections in employees and clients of small animal veterinary clinics and an animal shelter. *Salmonella* infections usually are acquired by eating contaminated food; however, direct contact with infected animals, including dogs and cats, also can result in exposure and infection (1). This report summarizes clinical and epidemiologic data about these outbreaks and reviews methods of reducing the likelihood of *Salmonella* transmission in veterinary settings by avoiding fecal-oral contact.

Idaho

During September–October, the Idaho Department of Health and Welfare identified through routine surveillance an outbreak of *Salmonella* infections among employees of a small animal veterinary clinic; 10 of 20 persons had abdominal cramps and diarrhea, and two of the 10 had bloody diarrhea. The median age of the ill persons was 31 years (range: 19–44 years), the median duration of illness was 7 days (range: 4–12 days), and four persons sought medical care. The index patient reported caring for several kittens with diarrhea 1 or 2 days before illness onset; stool specimens were not cultured and the kittens died. All 10 ill employees ate meals in the clinic and had no common exposures outside the clinic. Stool specimens from five ill employees yielded *S*. Typhimurium. All isolates were indistinguishable by pulsed-field gel electrophoresis (PFGE); reacted to phage but did not conform to a definitive phage type; and were resistant to ampicillin, ceftriaxone, cephalothin, chloramphenicol, clavulanic acid/amoxicillin, gentamicin, kanamycin, streptomycin, sulfamethoxazole, and tetracycline.

Minnesota

The Minnesota Department of Health (MDH) routinely receives animal *S.* Typhimurium isolates from the Minnesota Veterinary Diagnostic Laboratory. In 1999, MDH tested *S.* Typhimurium isolates from nine cats and seven humans that were indistinguishable by PFGE. All isolates were resistant to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole, and tetracycline (R-type ACSSuT). Three cat and two human isolates tested were definitive type (DT) 104. The cats had died in an animal shelter during September–October at age 6–14 weeks as a result of infection. The median age of

Salmonella Typhimurium — Continued

ill persons was 6 years (range: 11 months–23 years), and the median duration of diarrhea was 8 days (range: 5–11 days); all persons sought medical care, and one was hospitalized for 4 days. An adult treated with ciprofloxacin shed *S*. Typhimurium in stool at least 214 days after illness onset.

A connection with the animal shelter was established for six of the seven human patients; four purchased cats from the shelter during August–October and two attended the same day-care center as an ill child who owned a cat from the shelter. One cat developed bloody diarrhea 1 day after adoption and onset of illness in the patient began 4 days later. Two cats remained asymptomatic; however, the owner became ill 77 days after adopting the cats. The outbreak strain of *S.* Typhimurium was recovered from one cat 115 days after adoption.

Washington

Through laboratory-based surveillance and patient interviews, the Washington State Department of Health detected in late 1999 an outbreak of *Salmonella* infections associated with a small animal veterinary clinic. Stool specimens from three ill persons yielded *S*. Typhimurium, all three sought medical care, but none was hospitalized. One ill person was a clinic employee and the two others recently had brought their cats to the clinic, one for elective surgery and the other for a urinary tract infection. The cats developed diarrhea after their discharge from the clinic and the owners subsequently became ill. The clinic was the only common exposure reported by the three ill persons. *S*. Typhimurium was isolated from 14 cats associated with this clinic; some of the cats initially presented with diarrhea. Isolates from ill persons and cats were indistinguishable by PFGE. All isolates were DT104 R-type ACSSuT.

Reported by: H Ezell, B Tramontin, Idaho District Health Dept; R Hudson, PhD, Idaho State Public Health Laboratory; L Tengelsen, DVM, C Hahn, MD, State Epidemiologist, Idaho Dept of Health and Welfare. K Smith, DVM, J Bender, DVM, D Boxrud, J Adams, Minnesota Dept of Health; R Frank, DVM, Univ of Minnesota College of Veterinary Medicine, Dept of Veterinary Diagnostic Medicine; K Culbertson, DVM, Animal Humane Society, Golden Valley, Minnesota. T Besser, DVM, D Rice, MS, Washington State Univ College of Veterinary Medicine, Pullman; R Gautom, PhD, R Pallipamu, M Goldoft, MD, J Grendon, DVM, J Kobayashi, MD, Washington Dept of Health. F Angulo, DVM, T Barrett, PhD, S Rossiter, MPH, S Sivapalasingam, MD, J Wright, DVM, Foodborne and Diarrheal Diseases Br, Div of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, CDC.

Editorial Note: Although most of the estimated 1.4 million *Salmonella* infections that occur each year in the United States are transmitted through food, *Salmonella* also is transmitted through exposure to contaminated water, reptiles, farm animals, and pets (1). It is unknown how the human patients in these outbreaks became infected with *Salmonella*; however, the inadvertent ingestion of animal feces or food contaminated with animal feces may have occurred as the result of suboptimal sanitation and hygienic practices in the veterinary facilities. Many cats in these facilities had a diarrheal illness that also may have contributed to *Salmonella* transmission. Even after recovery from an acute episode of *Salmonella* gastroenteritis, fecal shedding of *Salmonella* can occur and may last several months. In addition, the use of antimicrobial agents in veterinary facilities may have contributed to transmission of multidrug-resistant *Salmonella* by lowering the infectious dose needed for ingestion to cause illness in animals and increasing the likelihood of transmission to humans. Although outbreaks of multidrug-resistant *Salmonella* with human and animal illness have been reported in large animal veterinary facilities (e.g., horse clinics) (*2*,*3*), outbreaks associated with small animal

Salmonella Typhimurium — Continued

facilities are rare. The outbreaks described in this report demonstrate that small animals shed *Salmonella* and that small animal facilities can serve as foci of transmission for *Salmonella* to other animals and humans.

In 1999, the most commonly isolated *Salmonella* serotype in the United States was *S*. Typhimurium, accounting for 23% of laboratory-confirmed *Salmonella* cases (4). Multidrug resistance among *S*. Typhimurium isolates is common; of human *S*. Typhimurium isolates received at CDC through the National Antimicrobial Resistance Monitoring System, 46% were multidrug-resistant; 61% of these were R-type ACSSuT and 23% were R-type AKSSuT (resistant to ampicillin, kanamycin, streptomycin, sulfamethoxazole, and tetracycline). R-type ACSSuT and R-type AKSSuT, the two most common multidrug-resistant *Salmonella* strains, accounted for 7% and 3% of non-Typhi *Salmonella* isolates, respectively (5). Investigations in the United States have found associations between human infections caused by R-type ACSSuT and R-type AKSSuT strains of *S*. Typhimurium and contact with cattle, including eating and drinking unpasteurized dairy products (*6*,*7*). *S*. Typhimurium DT104 R-type ACSSuT has been associated with contact with pets in the United Kingdom (*8*); outbreaks described in this report are the first to associate DT104 with pets in the United States.

To prevent salmonellosis, persons should wash their hands before eating and after handling food. Immunosuppressed persons should avoid animals aged <6 months and animals with diarrhea (9). Veterinary workers should wash their hands after handling pets, especially after handling feces. These workers can further reduce their exposure to feces by wearing rubber or disposable gloves, and by removing gloves and washing their hands immediately after finishing a task that involves contact with animal feces. Although there have been no reports of *Salmonella* transmission through splash exposures, workers might consider taking measures to reduce splashes of feces to the mouth when hosing or cleaning a kennel. All surfaces contaminated with feces should be cleaned and disinfected. No eating should be allowed in animal treatment or holding areas. Because use of antimicrobial agents contributes to increasing resistance and facilitates transmission of multidrug-resistant *Salmonella*, eliminating inappropriate use of antimicrobial agents of multidrug-resistant *Salmonella* infections in veterinary facilities (10).

References*

- Angulo FJ, Johnson KR, Tauxe RV, Cohen ML. Origins and consequences of antimicrobialresistant nontyphoidal *Salmonella*: implications for the use of fluoroquinolones in food animals. Microbial Drug Resist 2000;6:77–83.
- 2. Tillotson K, Savage CJ, Salman MD, et al. Outbreak of *Salmonella infantis* infection in a large animal veterinary teaching hospital. J Am Vet Med Assoc 1997;211:1554–7.
- 3. Hartmann FA, Callan RJ, McGuirk SM, et al. Control of an outbreak of salmonellosis caused by drug-resistant *Salmonella anatum* in horses at a veterinary hospital and measures to prevent future infections. J Am Vet Med Assoc 1996;209:629–31.
- CDC. Salmonella surveillance: annual tabulation summary, 1999. Atlanta, Georgia: US Department of Health and Human Services, CDC, 2000. Available at http://www.cdc.gov/ncidod/dbmd/narms/annuals.htm. Accessed August 2001.
- 5. CDC. National Antimicrobial Resistance Monitoring System 1999 annual report, Atlanta, Georgia: US Department of Health and Human Services, CDC, 1999.

^{*}All *MMWR* references are available on the Internet at <http://www.cdc.gov/mmwr>. Use the search function to find specific articles.

Salmonella Typhimurium — Continued

- Villar RG, Macek MD, Simons S, et al. Investigation of multidrug-resistant Salmonella serotype Typhimurium DT 104 infections linked to raw-milk cheese in Washington state. JAMA 1999;281:1811–6.
- 7. Fey PD, Safranek TJ, Rupp M, et al. Ceftriaxone-resistant *salmonella* infection acquired by a child from cattle. N Engl J Med 2000;342:1242–9.
- Wall PG, Morgan D, Lamden K, et al. A case control study of infection with an epidemic strain of multiresistant *Salmonella* Typhimurium DT104 in England and Wales. Commun Dis Rep 1994;4:R126–R131.
- CDC. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR 1999;48(no. RR 10).
- American Veterinary Medical Association. Principles on judicious therapeutic use of antimicrobials. Available at http://www.avma.org/scienact/jtua/default.asp. Accessed August 2001.

Tularemia — Oklahoma, 2000

In June 2000, seven cases of tularemia were reported to the Oklahoma State Department of Health (OSDH) over an 18-day period. Enhanced tularemia surveillance by OSDH during July–September 2000 detected four additional cases. During 1995–1999, an average of six cases were reported each year. This report summarizes clinical and epidemiologic information from the investigation of the 11 cases, presents three case reports to illustrate different risk factors for tularemia, and underscores the danger of delayed diagnosis of tularemia and the risk for acquiring tularemia in laboratory settings. Physicians should consider tularemia in ill persons with fever who reside in or visit areas where the disease is endemic and who have been exposed to ticks or carcasses or tissue from rabbits or other animals.

Cases were classified as either probable (i.e., compatible illness with laboratory findings indicative of presumptive infection [1]) or confirmed (i.e., compatible illness with confirmatory laboratory results). The median age of the 11 patients was 50 years (range: 3–77 years); six were female. All 11 resided in central or eastern Oklahoma. Symptoms included fever (11), cutaneous ulcer (seven), painful adenopathy (six), cough (five), and diarrhea (two). For surveillance purposes, OSDH staff categorized the clinical presentations as ulceroglandular (nine), typhoidal (one), and pneumonic (one) (1). Eight patients were hospitalized and two died. The median duration from onset of symptoms to tularemia diagnosis was 18 days (range: 3–57 days) for the nonfatal cases and 45 days for one fatal case; the date of onset was unknown for the second fatal case.

Eight cases, including both fatal cases, were confirmed either by culture (four patients) or four-fold rises in serum agglutination titer (four patients). Of the three probable cases, two patients had a single high titer (1:640 and 1:1280) and one was positive for IgM, IgA, and IgG antibody to *Francisella tularensis* by ELISA. Of the four culture-confirmed cases, *F. tularensis* was isolated from the blood of three patients and from the wound of the fourth patient. On the basis of testing at CDC, all three blood isolates were *F. tularensis* biovar tularensis (type A). Molecular typing by multiple-locus variable-number tandem repeat analysis at the Laboratory of Paul Keim, Northern Arizona University, indicated that the isolates were similar to seven other *F. tularensis* strains isolated in Oklahoma during 1992–1996.

Possible *F. tularensis* exposures for nonfatal cases included known tick attachment within 14 days of illness onset (three patients), possible environmental tick exposure (three patients), skinning rabbits (two patients), and laboratory exposure (one patient).

Tularemia — Continued

One person who died had possible tick exposure; the exposure for the other fatal case was undetermined.

Case Reports

Case 1. On June 16, 2000, a 64-year-old man was found comatose in his home and taken to a local emergency department (ED). In the ED, he had evidence of acute renal failure, and pulmonary infiltrates were seen on his chest radiograph. He had a history of fever of unknown duration, generalized muscle weakness, cough, hemoptysis, anorexia, and fatigue. Laboratory findings included marked elevation of creatine phosphokinase (>23,000 U/L) (normal=24–195 U/L), elevated blood urea nitrogen (120 mg/dL) (normal=8– 18 mg/dL) and creatine (7.5 mg/dL) (normal=0.2–0.5 mg/dL), white blood cell (WBC) count of 10.5x10³/cumm (normal=4.5–11x10³/cumm), elevated aspartate aminotransferase (AST) (720 U/L) (normal=0–35 U/L), alanine aminotransferase (ALT) (86 U/L) (normal=7– 35 U/L), total bilirubin (1.7 mg/dL) (normal=0.1–1.1 mg/dL), myoglobin (10,928 ng/mL) (normal=<116 ng/mL), and proteinuria. The patient was treated for acute renal failure and given intravenous ceftriaxone. Blood cultures performed on June 16 and 17 grew an organism that was identified as Actinobacillus actinomycemcomitans. The patient's condition deteriorated and, because he had a history of training dogs, intravenous doxycycline was started for a possible tickborne illness. The patient died on June 29. On July 14, F. tularensis was isolated from blood culture at the OSDH laboratory.

Case 2. On July 3, 2000, a 51-year-old female microbiologist presented to an ED with a 10-day history of fever, headache, myalgia, loss of appetite, abdominal tenderness, painful respiration, and sharp pain in the upper right quadrant of her back. Physical findings included fever (103 F [39.4 C]), cervical adenopathy, and a right lower lobe pulmonary infiltrate on chest radiograph. Laboratory findings included leukocytosis (WBC count of 14.8x10³/cumm), lymphocytosis (12.5x10³/cumm), elevated AST (61 U/L), ALT (121 U/L), and alkaline phosphatase (272 U/L) (normal=39–117 U/L). She was diagnosed with possible food poisoning and given a 10-day course of oral levofloxicin. Approximately 14 days before becoming symptomatic, she had worked with the blood culture bottles and plates obtained from case 1 in the hospital laboratory. When *F. tularensis* was isolated in case 1 specimens, case 2 was notified about a potential exposure to the organism. An agglutination titer performed on a blood specimen collected during ED examination was negative (<1:80), but a sample obtained 11 days later had a titer of 1:320. The patient recovered completely. None of the three other laboratory workers who had contact with case 1 specimens reported illness.

Case 3. On September 1, 2000, an 11-year-old girl with a 2-day history of fever (103 F [39.4 C]), painful adenopathy, headache, and muscle aches was taken to a hospital. On physical examination, she had cellulitis of the forearm and an enlarged axillary lymph node. Her peripheral blood count was normal. She was treated for cellulitis of undetermined etiology with an oral cephalosporin. When she did not improve after 3 days, she was taken to her regular physician who suspected tularemia and ordered serologic tests. Paired serum titers for *F. tularensis* collected 15 days apart were 1:40 and 1:1024, respectively. After taking doxycycline 100 mg/BID for 10 days, she recovered. The girl had a hobby of sewing together tanned rabbit hides to make blankets, and a week before illness onset she had skinned and tanned a rabbit killed by the family dog.

Reported by: K Bradley, DVM, M Grubbs, M Lytle, M Crutcher, MD, State Epidemiologist, Oklahoma State Dept of Health. K Smith, DVM, P Keim, PhD, The Laboratory of Paul Keim, Northern Arizona Univ, Flagstaff, Arizona. State Br, Div of Applied Public Health Training, Epidemiology Program Office; and an EIS Officer, CDC.

Tularemia — Continued

Editorial Note: *F. tularensis* is transmitted to humans by direct contact with or ingestion of infected animal tissues, through the bite of infected arthropods, by consumption of contaminated food or water, or from inhalation of aerosolized bacteria (2). It also is a potential bioterrorism agent (3). The occurrence of seven cases over a 2-week period in Oklahoma prompted an investigation of exposures, including the possibility of a bioterrorism event; however, the exposure history, clinical presentations, and geographic distribution of cases were compatible with natural transmission (3). In addition, the strains involved in this cluster were genetically similar to those previously acquired in the state.

Tularemia occurs throughout North America, but during 1985–1994, 55% of cases in the United States were reported from Arkansas, Missouri, and Oklahoma (4). The incidence of tularemia in the United States and in Oklahoma has declined markedly since the 1940s, and national incidence has remained between 0.05 and 0.15 cases per 100,000 population since 1965 (2). Reasons for the increase in cases in 2000 are unknown.

Tularemia has a broad clinical spectrum (2) and may be overlooked in the differential diagnosis of patients with suspected infectious diseases, particularly when the typical ulcer is absent. Delayed diagnosis and late administration of effective antibiotic therapy result in increased morbidity and mortality. Tularemia should be included in the differential diagnosis of any patient in an area where the disease is endemic who has unexplained febrile illness and exposure to ticks, biting flies, or animal tissue.

The acquisition of tularemia in a laboratory worker emphasizes the need to follow Biosafety Level 2 precautions when processing human specimens (5). Appropriate laboratory precautions include gloves, laboratory coats, face protection for manipulations outside a biosafety cabinet, use of a biosafety cabinet for procedures that may create aerosols, and decontamination of laboratory surfaces. Laboratory workers should wash their hands after removing gloves and before leaving the laboratory. Laboratory personnel should be informed of the possibility of tularemia as a differential diagnosis when samples are submitted for diagnostic tests. Work with cultures or contaminated materials should be performed at Biosafety Level 3 with all manipulations conducted in a biosafety cabinet, including preparations of materials for automated identification systems.

Information on the distribution of specific *F. tularensis* strains could provide a baseline reference for bioterrorism preparedness in the United States. For the public, education about risk factors for tularemia is the primary prevention measure.

References*

- 1. CDC. Case definitions for infectious conditions under public health surveillance. MMWR 1997;46(no. RR-10).
- Cross TJ, Penn RL. *Francisella tularensis* (tularemia). In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases, 5th ed. Philadelphia, Pennsylvania: Churchill Livingston, 2000.
- 3. Dennis DT, Inglesby TV, Henderson DA, et al. Tularemia as a biological weapon: medical and public health management. JAMA 2001;285:2763–73.
- 4. Dennis DT. Tularemia. In: Wallace RB, ed. Public Health and Preventive Medicine, 14th ed. Stamford, Connecticut: Appleton and Lang, 1998.
- 5. Richmond JY, McKinney RW. Biosafety in microbiological and biomedical laboratories, 4th ed. Washington, DC: CDC, National Institutes of Health, 1999.

^{*}All *MMWR* references are available on the Internet at <http://www.cdc.gov/mmwr>. Use the search function to find specific articles.


Outbreak of Pneumococcal Pneumonia Among Unvaccinated Residents of a Nursing Home — New Jersey, April 2001

On April 24, 2001, seven cases of pneumococcal pneumonia with bacteremia among residents of a nursing home were reported to the Hamilton Township Department of Health, New Jersey; all seven diagnoses were confirmed with blood cultures positive for *Streptococcus pneumoniae*. Illness onset among the residents occurred during April 3–24; four residents died. The New Jersey Department of Health and Senior Services (NJDHSS) was notified on April 24 and initiated an investigation to identify additional cases and implement control efforts. This report summarizes results of the investigation, which underscore the importance of providing pneumococcal polysaccharide vaccine (PPV) to elderly residents of long-term care facilities (LTCFs).

The nursing home is a 114-bed facility that employs approximately 200 staff, including nurses, restorative aides, and other administrative and support personnel. None of the employees was known to have pneumonia or laboratory-confirmed pneumococcal disease during this period.

On further investigation, two additional residents were identified to have been hospitalized during April 3–24 with pneumonia (Figure 1). Seven of the nine patients had blood cultures positive for *S. pneumoniae*, which were sent to the New Jersey Public Health

FIGURE 1. Number* of cases of pneumococcal pneumonia among residents of a nursing home, by week of symptom onset — Hamilton Township, New Jersey, March–April 2001



Week

Pneumococcal Pneumonia — Continued

and Environmental Laboratory and CDC for serotyping and susceptibility testing; pulsedfield gel electrophoresis was performed. All isolates were serotype 14, belonged to the England 14-9 clonal group, and were penicillin-sensitive and resistant only to erythromycin. Sputum specimens from the two remaining residents were Gram stain positive for diplococci and findings from chest radiographs were consistent with pneumonia. Seven of the residents lived in the same wing of the nursing home.

A case-control study was conducted to determine risk factors for pneumococcal pneumonia among residents of the nursing home. Cases included the nine residents hospitalized with pneumonia. Two controls per case-patient were selected randomly from among nursing home residents without pneumonia symptoms who resided in the wing where most of the case-patients resided during March 1–April 26. Nursing home medical records of case-patients and controls were reviewed, and a standardized form was used to abstract data.

Case-patients had a median age of 86 years (range: 78–100 years); seven (78%) were women. Controls had a median age of 85 years (58–95 years), and 17 (94%) were women. Illness was strongly associated with lack of documentation of receipt of PPV (none of nine case-patients versus nine of 18 controls; odds ratio=0; 95% confidence interval=0–0.7). Other exposures assessed but not associated with disease included recent antibiotic therapy, history of pneumonia, hospitalizations during the preceding year, medical conditions that are risk factors for pneumococcal disease*, and physical functioning (e.g., mobility and ability to eat and swallow).

At the time of the initial case of pneumococcal illness on April 3, 2001, 53 (49%) of the 108 residents had received PPV. When the outbreak was recognized, PPV was offered to all 55 nonvaccinated residents; 37 (67%) received vaccine. The remaining 18 were either ineligible for PPV or refused the vaccine. The nursing home also restricted transfers or admissions of patients with no history of having received PPV.

Following the investigation of the nursing home, the NJDHSS Division of Long Term Care Systems surveyed 361 LTCFs during May 21–July 31 about their vaccination policies. Of these, 28 (8%) did not meet the state regulation that requires offering PPV to every resident of a LTCF.

During May 24–June 7, the NJDHSS Division of Inspections, Compliance and Complaints investigated hospital compliance with the state regulation that requires offering PPV to every hospitalized patient aged \geq 65 years. Hospitals were selected if they had admitted residents of the nursing home before their long-term care placement or had admitted residents of this nursing home during the preceding year. The selected hospitals' infection control practitioners were interviewed to identify hospital policy on offering the vaccine to PPV-eligible patients. NJDHSS staff reviewed medical records of seven case-residents and randomly selected medical records of patients aged \geq 65 years to determine whether PPV was offered and administered.

Four hospitals were identified, and medical records of 52 patients were reviewed; at the time of the review, 49 of these 52 patients were discharged, and three remained hospitalized. Each hospital had a form to facilitate physician identification and documentation of PPV-eligible patients; 35 (67%) of 52 medical records contained completed screening or assessment forms. Of the 52 patients, 13 (25%) had received PPV before hospital admission and 34 (65%) had no history of having received PPV and no contraindications to the vaccine; none of these patients had documentation of receipt of PPV while hospitalized.

^{*}Chronic cardiovascular disease, chronic obstructive pulmonary disease, chronic liver disease, diabetes mellitus, and renal dysfunction.

Pneumococcal Pneumonia — Continued

Reported by: E Bresnitz, MD, State Epidemiologist, C Grant, S Ostrawski, C Morris, J Calabria, B Reetz, New Jersey Dept of Health and Senior Svcs; S Clugston, Hamilton Township Dept of Health, Hamilton, New Jersey. Respiratory Diseases Br, Div of Bacterial and Mycotic Diseases, National Center for Infectious Diseases; Epidemiology Program Office; and an EIS Officer, CDC.

Editorial Note: The findings in this report suggest that lack of pneumococcal vaccine may contribute to invasive pneumococcal disease in adults in LTCFs. Adults in LTCFs are especially vulnerable to pneumococcal disease and death because of their advanced age, the frequent presence of chronic illnesses, and residence in a setting that might increase the risk for bacterial transmission.

PPV is considered safe and is cost-effective and potentially cost-saving among persons aged \geq 65 years for prevention of bacteremia (1). Pneumococcal vaccinations are covered by Medicare, and virtually all state Medicaid plans cover vaccinations for highrisk groups (e.g., residents of nursing facilities). However, PPV coverage among elderly adults in LTCFs remains low, and outbreaks of pneumococcal pneumonia still occur in LTCFs with low vaccine coverage (2). In 1999, PPV coverage among a sample of nursing home residents in the United States was 38% (3). The low rate of PPV vaccination among institutionalized elderly has been attributed, in part, to a lack of physician emphasis on PPV administration (2). In addition, incomplete documentation of vaccination history of nursing home residents and misconceptions about adverse reactions after unintended revaccination with PPV may discourage health-care providers from vaccinating those with unknown vaccination history; however, the incidence of serious adverse events following revaccination is low (4). A study of Medicare inpatients indicated that opportunities to provide pneumococcal vaccines were missed for up to 80% of eligible elderly persons hospitalized with pneumonia (5).

One of the national health objectives for 2010 is to achieve 90% pneumococcal vaccination coverage among nursing home residents and adults aged \geq 65 years (objective 14-29) (6). Several methods have been developed for improving vaccine delivery. Standing orders programs, which authorize certain licensed health-care providers to administer vaccinations according to institutional and physician-approved protocols, improve vaccination rates in adults (7). Regulations that mandate hospitals, adult day-care facilities, and LTCFs, including nursing homes and assisted living facilities, to offer and document pneumococcal vaccinations may improve vaccination coverage for LTCF residents. However, this investigation highlights the limitations of regulations for ensuring vaccine coverage. Better documentation would facilitate tracking of the vaccination status of residents and provide medical history information to other health-care facilities when a resident is hospitalized or transferred or if an outbreak of pneumococcal illness occurred.

For this report, only 361 of 853 LTCFs in New Jersey had been evaluated to date for compliance with the state's vaccination requirements. These facilities may not be representative of all LTCFs in New Jersey.

This outbreak underscores the importance of providing pneumococcal vaccines to LTCF residents. The outbreak occurred in a setting of low vaccination coverage despite state regulations designed to improve vaccine delivery. A multifaceted approach that both facilitates delivery through standing orders programs and increases awareness of the importance of preventing pneumococcal disease may be needed to ensure optimal vaccine delivery to LTCF residents.

Pneumococcal Pneumonia — Continued

References[†]

- 1. Sisk JE, Moskowitz AJ, Whang W, et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 1997;278:1333–9.
- CDC. Outbreaks of pneumococcal pneumonia among unvaccinated residents in chroniccare facilities—Massachusetts, October 1995, Oklahoma, February 1996, and Maryland, May–June 1996. MMWR 1997;46:60–2.
- Buikema AR, Singleton JA, Sneller VP, et al. Influenza and pneumococcal vaccination in nursing homes, U.S., 1995–1999. [Abstract]. Presented at the National Immunization Conference, Atlanta, Georgia, May 2001.
- 4. Jackson LA, Benson P, Sneller VP, et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 1999;281:243–8.
- CDC. Missed opportunities for pneumococcal and influenza vaccination of Medicare pneumonia inpatients—12 western states, 1995. MMWR 1997;46:919–23.
- 6. US Department of Health and Human Services. In: Healthy people 2010 (conference ed, 2 vols). Washington, DC: US Department of Health and Human Services, 2000.
- Task Force on Community Preventive Services. Recommendations regarding interventions to improve vaccination coverage in children, adolescents, and adults. Am J Prev Med 2000;18:92–6.

Public Health Dispatch

Adverse Events and Deaths Associated With Laboratory Errors at a Hospital — Pennsylvania, 2001

On August 3, CDC was contacted by the Pennsylvania Department of Health (PADOH) to assist with an investigation of laboratory errors that may have contributed to the deaths of two persons taking the anticoagulant drug warfarin (Coumadin®*) (DuPont Pharmaceuticals Company, Wilmington, Delaware). The Food and Drug Administration (FDA) also is conducting an investigation of these incidents. Warfarin inhibits blood clotting and is prescribed for the management and prevention of conditions such as strokes, clots in the veins, and heart attacks. Physicians routinely monitor warfarin's anticoagulation effect on the blood by following two laboratory results: the prothrombin time (PT) and the International Normalized Ratio (INR). The INR is a numeric value calculated from the PT; the World Health Organization recommends the INR to standardize PT results from various manufacturers' devices and testing reagents (1). Physicians use INR to compare test results performed at different laboratories.

During June 4–July 25, a hospital laboratory in Pennsylvania reported 2146 tests with correct PT results but with incorrectly calculated INR results. The mathematical formula required to calculate the INR uses a reagent-specific number, the International Sensitivity Index (ISI). In June, the hospital laboratory did not verify the new reagent used in the PT measurement device; as a result, the ISI used to calculate INR was incorrect for the reagent used. For approximately 7 weeks, the reported INRs were falsely low. Some physicians who received these reports increased their patients' doses of warfarin. In

[†] All *MMWR* references are available on the Internet at <http://www.cdc.gov/mmwr>. Use the search function to find specific articles.

^{*}Use of trade names and commercial sources is for identification only and does not constitute endorsement by CDC or the U.S. Department of Health and Human Services.

Public Health Dispatch — Continued

addition to investigations into the two deaths, efforts are under way by PADOH Bureau of Laboratories, Centers for Medicare and Medicaid Services (CMS), and CDC to identify other patient morbidity and mortality associated with the error, its possible causes, and the steps needed to prevent its recurrence. FDA is reviewing possible deficiencies in the manufacturer's reagent package labeling.

To avoid the combination of events preceding the errors in Pennsylvania, laboratories reporting PT and INR should review the reagent package insert information or consult the reagent manufacturer to verify that the correct ISI for both the instrument and the particular lot of reagent being used is identified and applied correctly to the calculation of the INR. Laboratories should provide and physicians should consider using both the PT and the INR when contemplating a change in a patient's warfarin dose. Warfarin is one of the most common drugs associated with medication errors, and appropriate warfarin use has been identified as an important indicator of high-quality health care and patient safety (2,3). Incorrect laboratory reporting of INR results further contributes to the risk for complications of warfarin use.

The Safe Medical Devices Act of 1990 requires hospitals and other patient facilities to report to FDA deaths and serious injuries associated with the use of medical devices, including clinical laboratory assays and equipment. FDA also encourages health-care providers to voluntarily report through MedWatch product problems or concerns related to medical devices. Confidentiality of voluntary reporters is maintained on request. Information about FDA's mandatory and voluntary adverse event reporting programs is available at <http://www.fda.gov/medwatch>[†] or by telephoning (800) 322-1088. To monitor and prevent adverse patient events and medical errors, CDC, the Agency for Healthcare Research and Quality, CMS, and FDA are participating in the Patient Safety Task Force, a federal initiative to reduce the occurrence of injuries that result from medical errors. Information is available at <http://www.ahrq.gov/qual/taskforce/psfactst.htm>. Additional information on CDC's efforts to monitor and prevent adverse patient events and medical errors.

Reported by: Office of the Director, Div of Healthcare Quality Promotion, National Center for Infectious Diseases, CDC.

References

- Riley RS, Rowe D, Fisher LM. Clinical utilization of the international normalized ratio (INR). J Clin Lab Anal 2000;14:101–14.
- Summary of 1999 information submitted to MedMARx: a national database for hospital medication error reporting. Rockville, Maryland: U.S. Pharmacopeia, 2000. Available at https://www.medmarx.com/medmarx. Accessed August 2001.
- 3. Jencks SF, Cuerdon T, Burwen DR, et al. Quality of medical care delivered to Medicare beneficiaries: a profile at state and national levels. JAMA 2000;284:1670–6.

[†] References to sites of non-CDC organizations on the World-Wide Web are provided as a service to *MMWR* readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites.

Notice to Readers

Final 2000 Reports of Notifiable Diseases

The notifiable diseases tables on pages 721 to 728 summarize final data for 2000. Final as of July 25, 2001, these data will be published in more detail in the *Summary of Notifiable Diseases, United States, 2000* (1). Because no cases of western equine encephalitis, paralytic poliomyelitis, or yellow fever were reported in the United States during 2000, these nationally notifiable diseases do not appear in these tables. Policies for reporting notifiable disease cases can vary by disease or reporting jurisdiction depending on case status classification (i.e., confirmed, probable, or suspect). Population estimates for the states are from the U.S. Bureau of the Census: 1991–1999 Estimates of the Population of Counties by Age, Sex and Race/Hispanic Origin: 1990 to 1999 (machine-readable files). Population numbers for territories are 1998 estimates from Bureau of the Census press releases PR-99-1 (*2*) and CB98-219 (*3*).

References*

- 1. CDC. Summary of notifiable diseases, United States, 2000. MMWR 2000;49(no. 53)(in press).
- 2. US Bureau of the Census. Estimates of the population of Puerto Rico Municipios, July 1, 1999, and demographic components of population change: April 1, 1990 to July 1, 1999 (includes revised April 1, 1990 census population counts). [Press release]. Available at http://www.census.gov/population/estimates/puerto-rico/prmunnet.txt. Accessed August 2001.
- US Bureau of the Census. Census Bureau estimates population of insular areas. [Press release]. Available at http://www.census.gov/Press-Release/www/1999/cb99-254.html>. Accessed August 2001.

^{*}All *MMWR* references are available on the Internet at <http://www.cdc.gov/mmwr>. Use the search function to find specific articles.




FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 4-week totals ending August 18, 2001, with historical data

* Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

		Cum. 2001		Cum. 2001
Anthrax		-	Poliomyelitis, paralytic	-
Brucellosis*		50	Psittacosis*	9
Cholera		4	Q fever*	15
Cyclosporiasis	*	103	Rabies, human	1
Diphtheria		1 1	Rocky Mountain spotted fever (RMSF)	291
Ehrlichiosis:	human granulocytic (HGE)*	115	Rubella, congenital syndrome	-
	human monocytic (HME)*	45	Streptococcal disease, invasive, group A	2,497
Encephalitis:	California serogroup viral*	13	Streptococcal toxic-shock syndrome*	43
	eastern equine*	3	Syphilis, congenital §	84
	St. Louis [*]	-	Tetanus	16
	western equine*	-	Toxic-shock syndrome	82
Hansen diseas	se (leprosy)*	47	Trichinosis	14
	Imonary syndrome*	4	Tularemia*	62
	mic syndrome, postdiarrheal*	69	Typhoid fever	164
HIV infection,	pediatric*1	98	Yellow fever	-
Plaque	•	2		

TABLE I. Summary of provisional cases of selected notifiable diseases, United States, cumulative, week ending August 18, 2001 (33rd Week)

-: No reported cases. *Not notifiable in all states.

¹ Updated monthly from reports to the Division of HIV/AIDS Prevention — Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention (NCHSTP). Last update June 26, 2001. [§]Updated from reports to the Division of STD Prevention, NCHSTP.

							Escherichia coli O157:H7*			
_	Cum.	DS Cum.	Cum.	nydia [†] Cum.	Cum.	ooridiosis Cum.	NET Cum.	Cum.	Cum.	LIS Cum.
Reporting Area	2001 [§] 19,145	2000 24,193	2001 422,782	2000 436,556	2001 1,273	2000 1,258	2001 1,375	2000 2,516	2001 1,123	2000 2,262
NEW ENGLAND Maine N.H. Vt. Mass. R.I. Conn.	746 20 17 10 411 53 235	1,327 20 21 27 837 54 368	13,910 668 809 372 6,437 1,659 3,965	14,711 902 649 340 6,259 1,606 4,955	60 9 3 22 19 3 4	76 12 9 17 25 2 11	145 17 22 10 75 6 15	241 17 21 24 115 11 53	138 15 18 5 72 6 22	254 19 24 26 116 11 58
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	3,974 322 1,996 960 696	5,674 606 3,136 1,119 813	47,937 8,446 19,132 6,458 13,901	40,903 876 16,932 7,416 15,679	148 57 58 4 29	198 53 100 9 36	100 75 7 18 N	266 160 17 89 N	103 66 8 29	192 38 13 87 54
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	1,408 237 165 665 261 80	2,288 345 216 1,289 329 109	60,430 8,993 9,102 16,609 18,695 7,031	75,176 19,421 8,189 21,150 16,186 10,230	379 88 41 1 91 158	331 36 20 50 46 179	323 89 50 73 45 66	577 88 72 131 68 218	236 65 25 80 39 27	487 138 61 102 65 121
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. Nebr. Kans.	454 85 47 218 1 18 39 46	600 115 60 285 2 4 38 96	21,524 4,092 1,858 8,443 589 957 2,038 3,547	24,498 5,011 3,351 8,388 567 1,128 2,305 3,748	168 86 42 13 6 15	134 21 40 19 7 9 33 5	227 92 39 9 13 31 14	370 93 103 78 8 25 46 17	207 91 31 42 19 17 - 7	373 111 89 72 15 38 36 12
S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	6,167 116 751 465 501 49 402 350 757 2,776	6,439 111 837 448 461 37 372 525 704 2,944	81,351 1,811 7,301 1,764 11,814 1,480 12,922 7,413 15,221 21,625	81,204 1,833 8,625 1,983 9,981 1,329 14,050 5,402 17,181 20,820	197 2 28 9 15 1 19 - 71 52	196 4 8 5 3 16 - 83 71	119 2 9 - 33 4 28 6 17 20	187 1 14 38 10 38 14 31 41	73 4 1 20 3 17 9 12 7	196 - 1 U 41 7 46 12 36 53
E.S. CENTRAL Ky. Tenn. Ala. Miss.	977 201 293 224 259	1,223 128 531 301 263	29,923 5,573 8,856 8,269 7,225	31,588 5,008 8,961 9,775 7,844	27 3 6 10 8	36 5 9 11 11	70 33 23 11 3	80 24 33 5 18	61 33 25 - 3	75 25 38 4 8
W.S. CENTRAL Ark. La. Okla. Tex.	2,058 104 472 107 1,375	2,543 111 367 185 1,880	64,468 4,455 10,420 6,809 42,784	65,820 4,159 11,844 5,065 44,752	21 5 7 7 2	66 5 10 4 47	41 4 2 18 17	181 46 13 9 113	57 - 24 18 15	222 32 34 11 145
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	714 12 15 1 140 56 295 63 132	870 9 16 7 200 89 244 94 211	24,008 1,015 1,075 514 4,768 3,621 9,109 996 2,910	25,280 960 1,169 501 7,537 3,073 8,141 1,444 2,455	82 7 8 1 24 12 4 23 3	53 8 3 5 15 4 5 10 3	153 8 22 7 59 8 20 21 8	248 24 36 11 94 12 35 30 6	86 - 1 44 8 9 23 1	185 - 22 8 66 13 26 43 7
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	2,647 290 112 2,204 13 28	3,229 291 107 2,733 12 86	79,231 8,648 2,814 63,786 1,697 2,286	77,376 8,133 4,360 61,122 1,533 2,228	191 37 18 132 1 3	168 U 11 157 -	197 52 27 105 3 10	366 117 61 157 22 9	162 31 23 105 3	278 136 67 66 1 8
Guam P.R. V.I. Amer. Samoa C.N.M.I.	9 580 2 -	13 758 24 -	- 1,638 53 U 85	323 U U U U	- - - U -	- - - U U	N 1 - U -	N 5 U U		U U U U U

TABLE II. Provisional cases of selected notifiable diseases, United States,
weeks ending August 18, 2001, and August 19, 2000 (33rd Week)

N: Not rotifiable. U: Unavailable. -: No reported cases. C.N.M.I.: Commonwealth of Northern Mariana Islands. *Individual cases can be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS). * Chlamydia refers to genital infections caused by *C. trachomatis.* * Updated monthly from reports to the Division of HIV/AIDS Prevention — Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention. Last update June 26, 2001.

	Gonor	rrhea	Hepatit Non-A, N		Legione	llosis	Listeriosis		me ease
Reporting Area	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2001	Cum. 2000
UNITED STATES	194,140	219,099	2,270	2,088	574	581	274	6,105	9,782
NEW ENGLAND Maine N.H. Vt. Mass.	3,872 79 107 47 1,969	4,151 51 66 41 1,683	14 - - 6 8	20 2 4 10	28 3 7 4 6 2	29 2 3 14 3	31 - 2 15 1	1,610 - 84 4 348	2,834 - 36 18 917
R.I. Conn.	422 1,248	390 1,920	-	4	2 6	3 5	11	197 977	211 1,652
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	23,825 5,201 8,016 3,830 6,778	23,412 4,240 7,207 4,590 7,375	975 38 - 896 41	440 23 - 385 32	115 38 6 5 66	153 38 21 14 80	42 17 7 7 11	3,306 1,740 1 448 1,117	5,262 1,845 153 2,049 1,215
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	32,810 5,338 3,803 10,443 10,791 2,435	44,226 11,560 3,797 13,152 11,340 4,377	116 7 1 11 97	169 7 17 145	138 74 14 - 30 20	154 59 24 21 26 24	32 11 4 1 14 2	339 75 9 1 254	622 41 17 30 20 514
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. Nebr.	9,197 1,334 428 5,034 19 144 692	10,807 2,006 713 5,313 42 181 889	459 6 446 - - 3	390 5 1 374 - 3	39 9 6 14 1 3 5	42 3 10 21 - 2 2	7 - - 4 - - 1	194 150 22 15 - - 3	146 76 17 36 -
Kans. S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	1,546 50,161 1,039 4,003 1,558 6,853 389 10,657 5,199 8,202 12,261	1,663 57,091 1,052 5,817 1,517 6,268 408 11,474 5,244 10,888 14,423	4 71 - 9 13 5 - 32	7 63 2 8 2 3 12 13 1 2 20	1 121 3 25 7 17 N 7 5 9 48	4 98 5 36 - 14 N 9 4 6 24	2 45 - 8 4 2 4 7 13	4 528 31 341 8 9 26 3 - 21	14 759 158 442 91 22 31 3 - 10
E.S. CENTRAL Ky. Tenn. Ala. Miss.	19,252 2,195 5,904 6,415 4,738	22,457 2,169 7,045 7,515 5,728	146 5 46 2 93	303 25 62 7 209	41 9 21 9 2	20 11 6 2 1	12 4 4 -	30 17 7 6	31 6 19 3 3
W.S. CENTRAL Ark. La. Okla. Tex.	31,449 2,739 7,295 3,120 18,295	34,426 2,323 8,573 2,186 21,344	162 3 75 3 81	529 6 287 6 230	5 - 2 3 -	20 - 7 2 11	6 1 - 2 3	7 - 1 - 6	56 5 5 - 46
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	6,307 53 43 1,953 592 2,492 88 1,043	6,631 28 57 36 2,018 666 2,764 148 914	234 1 190 14 11 9 2 6	48 4 3 9 11 13 6	40 2 4 11 2 11 7 3	24 1 - 7 1 6 5 -	25 - 1 5 6 6 1 5	10 - 4 3 1 - - 1 1	5 - 1 2 - - - 2
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	17,267 1,946 410 14,303 238 370	15,898 1,409 583 13,410 201 295	93 16 10 67	126 20 21 83 - 2	47 6 N 37 - 4	41 14 N 27 -	74 5 3 62 - 4	81 5 69 2 N	67 3 57 57 2 N
Guam P.R. V.I. Amer. Samoa C.N.M.I.	382 6 U 7	32 334 - U U	- 1 - U	2 1 - U U	2 - U	- 1 - U U	- - -	N U	- N - U U
	, 	0		0		0			0

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States,
weeks ending August 18, 2001, and August 19, 2000 (33rd Week)

N: Not notifiable. U: Unavailable. -: No reported cases.

						Salmon	ellosis*	
		laria		s, Animal		TSS		ilis
Reporting Area	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000
UNITED STATES	674	844	3,881	4,346	19,966	22,398	16,091	19,698
NEW ENGLAND Maine N.H. Vt. Mass. R.I. Conn.	35 3 2 11 3 16	44 4 1 2 18 5 14	411 45 16 39 155 34 122	489 89 9 40 159 28 164	1,409 133 124 44 834 66 208	1,392 89 86 79 823 65 250	1,378 102 116 45 701 110 304	1,449 68 89 78 826 99 289
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	159 39 74 21 25	199 41 105 28 25	755 479 20 111 145	789 494 6 104 185	2,666 719 662 590 695	3,076 706 784 746 840	2,360 622 790 527 421	3,188 824 799 601 964
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	66 19 13 1 20 13	100 13 5 51 21 10	68 23 1 9 29 6	92 25 16 40 11	2,792 855 320 684 501 432	3,037 682 366 984 559 446	2,453 683 298 704 525 243	2,047 829 379 1 603 235
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. Nebr. Kans.	24 6 4 8 - 2 4	37 13 1 9 2 - 6 6	213 24 49 22 24 25 4 65	389 58 55 32 94 72 1 77	1,272 382 200 331 37 80 96 146	1,454 340 213 449 34 57 126 235	1,352 438 193 467 51 86 - 117	1,642 452 217 547 56 69 100 201
S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	191 1 78 13 37 1 9 5 12 35	182 3 68 13 35 2 15 1 4 41	1,391 25 178 273 92 377 84 223 139	1,470 31 270 376 80 376 86 157 94	4,964 59 483 55 865 74 701 490 778 1,459	4,246 75 476 35 553 95 584 431 729 1,268	3,122 61 481 U 497 83 570 440 745 245	3,564 87 426 596 92 657 332 1,073 301
E.S. CENTRAL Ky. Tenn. Ala. Miss.	20 8 8 3 1	25 8 6 10 1	137 15 82 40	126 17 69 39 1	1,228 202 327 382 317	1,292 232 335 338 387	950 137 409 294 110	1,050 175 482 323 70
W.S. CENTRAL Ark. La. Okla. Tex.	9 3 3 2 1	56 2 10 4 40	509 19 - 48 442	604 20 2 42 540	1,420 394 252 228 546	2,842 381 480 243 1,738	1,213 92 424 186 511	1,735 325 390 181 839
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	33 2 3 - 17 2 3 3 3 3	32 1 2 - 17 - 5 3 4	163 26 11 21 - 8 93 3 3 1	181 47 8 40 - 14 62 8 2	1,319 47 90 44 369 152 385 137 95	1,692 69 86 43 469 150 396 304 175	808 4 22 276 136 216 131 23	1,617 76 38 460 146 425 304 168
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	137 4 8 117 1 7	169 15 27 118 - 9	234 1 196 37	206 5 176 25	2,896 302 155 2,186 27 226	3,367 318 202 2,669 36 142	2,455 358 215 1,701 2 179	3,406 424 257 2,554 24 147
Guam P.R. V.I. Amer. Samoa C.N.M.I.	3 - U	- 4 - U U	64 U	- 53 - U U	335 - U 8	19 396 - U U	U U U U	

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States,
weeks ending August 18, 2001, and August 19, 2000 (33rd Week)

N: Not notifiable. U: Unavailable. -: No reported cases. *Individual cases can be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS).

		Shige				philis		
-	NET	SS Cum.	Cum.	HLIS Cum.	(Primary 8 Cum.	& Secondary) Cum.	Cum.	rculosis Cum.
Reporting Area	2001	2000	2001	2000	2001	2000	2001	2000
JNITED STATES	9,825	13,495	4,587	7,549	3,494	3,826	7,472	8,707
NEW ENGLAND Maine N.H. Vt. Mass. R.I. Conn.	155 6 4 6 109 8 22	249 6 4 3 176 19 41	156 2 2 102 19 29	239 11 7 158 22 41	32 - 1 2 18 3 8	55 1 - - 38 4 11	276 7 11 2 157 21 78	257 9 13 4 151 24 56
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	898 355 249 145 149	1,801 501 751 367 182	565 76 267 157 65	1,150 176 489 308 177	306 19 161 69 57	182 7 76 44 55	1,459 197 762 323 177	1,442 189 778 340 135
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	2,456 1,687 145 256 194 174	2,802 201 1,049 802 522 228	1,088 697 27 204 141 19	808 172 123 2 472 39	582 53 111 154 247 17	787 52 243 275 181 36	752 133 64 385 135 35	852 195 83 376 140 58
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. Nebr. Kans.	974 286 301 176 16 92 54 49	1,467 444 325 482 4 4 70 138	785 318 249 126 17 51 - 24	1,258 521 249 339 14 3 57 57 75	47 21 8 - 2 15	48 8 10 25 - 2 3	278 142 18 86 3 8 21	317 100 25 122 2 13 12 43
S. ATLANTIC Del. Md. D.C. Va. W. Va. W. Va. N.C. S.C. Ga. Fla.	1,420 6 80 37 173 7 240 174 147 556	1,715 11 120 34 284 3 103 84 152 924	417 7 45 57 7 112 89 81 19	639 12 59 U 229 3 76 63 125 72	1,246 8 144 24 73 - 294 168 198 337	1,269 5 192 24 85 2 337 138 241 245	1,520 9 131 47 155 20 206 128 249 575	1,757 8 159 15 178 21 240 164 381 591
E.S. CENTRAL Ky. Tenn. Ala. Miss.	876 324 60 165 327	609 208 241 34 126	385 169 72 119 25	346 50 267 26 3	392 29 208 87 68	559 58 340 78 83	466 76 167 158 65	566 70 211 184 101
W.S.CENTRAL Ark. La. Okla. Tex.	1,042 401 108 30 503	2,165 138 190 <i>7</i> 5 1,762	705 155 124 14 412	648 43 117 29 459	439 22 91 47 279	521 67 141 <i>7</i> 5 238	702 95 95 512	1,293 130 94 101 968
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	569 24 2 144 68 250 42 37	636 6 41 4 110 80 253 48 94	269 - - 80 43 99 39 8	446 23 3 75 55 172 53 65	149 - - 26 13 99 7 4	146 1 6 12 121 1	2777 8 2 78 16 108 20 45	317 10 4 2 47 28 131 30 65
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	1,435 129 54 1,207 4 41	2,051 338 117 1,565 7 24	217 119 70 1 27	2,015 310 75 1,605 3 22	301 34 5 256 6	259 47 10 201 1	1,742 158 65 1,401 27 91	1,906 151 61 1,536 69 89
Guam P.R. V.I. Amer. Samoa	- 7 - U	33 22 U	U U U U		172 U	2 110 Ū	- 54 - U	35 92 - U
C.N.M.I. N: Not notifiable.	0 4 U: Unav	U	U	U rted cases.	-	U	20	U

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States, weeks ending August 18, 2001, and August 19, 2000 (33rd Week)

N: Not notifiable. U: Unavailable. -: No reported cases. *Individual cases can be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS).

			1	-		, ZUUU (JSTCI WEEK) , By Type Measles (Rubeola)						
		<i>ienzae,</i> isive	A	epatitis (Vi	iral), By Ty B	pe	Indige	nous	Inpo		Total	
Poporting Area	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	2001	Cum.	2001	Cum.	Cum.	Cum.
Reporting Area UNITED STATES	2001 [†] 887	<u>2000</u> 843	2001 5,995	2000 8,054	2001 4,049	2000 4,356	-	2001 50	-	<u>2001</u> 35	2001 85	2000 61
NEW ENGLAND	48	64	308	244	59	72	-	4	-	1	5	6
Maine N.H.	1 2	1 11	5 11	13 17	5 11	5 11	-	-	-	-	-	- 3
Vt. Mass.	2 33	5 31	8 118	7 95	3 2	6 8	-	1 2	-	- 1	1 3	3
R.I. Conn.	2 8	1 15	16 150	15 97	14 24	13 29	-	- 1	-	-	- 1	-
MID. ATLANTIC	125	159	648	890	633	774	-	4	-	10	14	20
Upstate N.Y. N.Y. City	49 31	64 43	167 190	144 309	85 298	83 377	-	1 2	-	4 1	5 3	9 10
N.J. Pa.	30 15	30 22	159 132	166 271	64 186	121 193	-	- - 1	-	1 4	1 5	- 1
E.N. CENTRAL	121	129	636	1,060	574	462	_	-	-	4 10	10	6
Ohio Ind.	50 36	40 22	152 59	176 45	75 30	74 30	-	-	-	3 4	3 4	2
III. Mich.	10 7	42 9	179 207	473 308	92 377	80 255	-	-	-	3	3	3 1
Wis.	, 18	16	39	58	-	255	-	-	-	-	-	-
W.N. CENTRAL Minn.	44 25	44 22	252 16	519 143	120 12	194 23	-	4 2	-	-	4 2	1 1
lowa Mo.	13	- 14	25 63	53 224	15 62	19 103	-	- 2	-	-	- 2	-
N. Dak.	4	2	2	2	-	2	-	-	-	-	-	-
S. Dak. Nebr.	- 1	- 3	1 28	23	1 17	29	U -	-	U -	-	-	-
Kans.	1	3	117	74	13	18	-	-	-	-	-	-
S. ATLANTIC Del.	261	197	1,352	823 10	850	731 10	-	4	-	1	5	2
Md. D.C.	62	54 -	176 33	111 19	92 11	82 19	-	2	-	1 -	3	-
Va. W. Va.	19 10	32 5	83 8	97 48	97 20	95 8	-	1	-	-	1	2
N.C. S.C.	32 5	19 7	99 50	103 34	131 19	157 7	-	-	-	-	-	-
Ga. Fla.	67 66	50 30	535 368	144 257	208 272	122 231	-	1	-	-	1	-
E.S. CENTRAL	58	30 36	233	294	272	308	_	2	_	-	2	_
Ky. Tenn.	2 29	12 15	62 95	35 103	27 141	58 146	-	2	-	-	2	-
Ala. Miss.	26 1	7	63 13	43 113	58 47	34 70	Ū	-	Ū	-	-	-
WISS. W.S. CENTRAL	34	47	625	1,538	427	655	-	- 1	-	-	- 1	-
Ark. La.	3	1 14	49 49	104 54	60 29	67 97	-	-	-	-	-	-
Okla. Tex.	31	30 2	94 433	175 1,205	64 274	95 396	-	- 1	-	-	- 1	-
MOUNTAIN	116	83	433 538	570	357	336		-		- 1	1	- 12
Mont. Idaho	- 1	1	8 48	4 19	2	4	-	-	-	- 1	- 1	-
Wyo. Colo.	17	1	22 50	4	31	1	-	-	-	-	-	-
N. Mex.	27 14	17 17	27	136 51	73 88	54 102	-	-	-	-	-	2
Ariz. Utah	42 6	34 7	282 58	274 39	107 18	124 16	-	-	-	-	-	3
Nev.	9	3	43	43	29	30	U	-	U	-	-	7
PACIFIC Wash.	80 2	84 3	1,403 87	2,116 187	756 80	824 54	-	31 13	-	12 2	43 15	14 3
Oreg. Calif.	17 33 5	23 30	56 1,245	137 1,768	49 605	69 683	-	3 12	-	- 6	3 18	- 8
Alaska Hawaii	5 23	6 22	14 1	11 13	7 15	9 9	-	- 3	-	- 4	-7	1 2
Guam	-	1	-	1	-	9	U	-	U	-	-	-
P.R. V.I.	1	3	62	185	106	182	U U	-	U U	-	-	2
Amer. Samoa C.N.M.I.	U -	U U	U -	U U	U 24	U U	U U	U -	U U	U -	U -	U U

TABLE III. Provisional cases of selected notifiable diseases preventable
by vaccination, United States, weeks ending August 18, 2001,
and August 19, 2000 (33rd Week)

N: Not notifiable. U: Unavailable. - : No reported cases. *For imported measles, cases include only those resulting from importation from other countries. † Of 178 cases among children aged <5 years, serotype was reported for 84, and of those, 14 were type b.

		gococcal		just 19,	2000							
	Dise Cum.	ease Cum.		Mumps Cum.	Cum.		Pertussis Cum.	Cum.		Rubella Cum.	Cum.	
	2001	2000	2001	2001	2000	2001	2001	2000	2001	2001	2000	
UNITED STATES NEW ENGLAND Maine	1,529 82 1	1,506 88 7	4 -	141 - -	236 4	59 - -	2,788 277	3,849 995 14	1 -	17 - -	107 11	
N.H.	10	9	-	-	-	-	25	79	-	-	2	
Vt. Mass.	5 47	2 51	-	-	- 1	-	25 211	165 690	-	-	- 8	
R.I. Conn.	2 17	6 13	-	-	1 2	-	2 14	12 35	-	-	- 1	
MID. ATLANTIC	165	172	-	15	18	4	209	360	-	5	8	
Upstate N.Y. N.Y. City	46 31	47 35	-	3 9	5 6	4	115 34	166 52	-	1 3	1 7	
N.J. Pa.	39 49	32 58	-	- 3	3 4	-	8 52	24 118	-	1 -	-	
E.N. CENTRAL	195	260	1	15	18	18	342	435	-	3	1	
Ohio Ind.	67 28	59 31	-	1 1	7	9 9	201 46	203 52	-	- 1	-	
III. Mich.	20 46	66 75	- 1	10 3	6 4	-	35 36	44 52	-	2	1	
Wis.	34	29	-	-	1	-	24	84	-	-	-	
W.N. CENTRAL Minn.	103 15	102 14	1 1	7 3	13	16 16	150 47	244 142	-	3	1	
lowa Mo.	21 39	21 50	-	-	6 4	-	17 65	30 37	-	1 1	-	
N. Dak. S. Dak.	5	2	-	-	-	-	-	2	-	-	-	
Nebr.	4 10	5 4	U -	- 1	- 1	U -	3 4	3 5	U -	-	- 1	
Kans. S. ATLANTIC	9 291	6 217	- 1	3 23	2 35	- 3	14 149	25 289	- 1	1 4	- 60	
Del.	3	-	-	-	-	-	-	8	-	4	-	
Md. D.C.	34 -	22	-	4	8 -	-	18 1	76 3	-	-	-	
Va. W. Va.	30 11	34 10	-	5	6	- 1	27 2	41 1	-	-	-	
N.C. S.C.	57 29	31 15	-	1 2	5 10	- 1	46 25	69 21	-	2	52 6	
Ga. Fla.	36 91	37 68	- 1	7 4	2 4	- 1	7 23	25 45	- 1	- 2	2	
E.S. CENTRAL	101	103	-	3	4	3	75	83	-	-	5	
Ky. Tenn.	18 44	21 42	-	1	- 2	2	17 31	42 25	-	-	1 1	
Ala. Miss.	29 10	29 11	- U	- 2	2	1 U	24 3	13 3	- U	-	3	
W.S. CENTRAL	171	162	-	8	25	4	238	201	-	-	7	
Ark. La.	12 56	11 36	-	1 2	1 5	-	8 2	29 13	-	-	1 1	
Okla. Tex.	23 80	22 93	-	- 5	19	- 4	1 227	9 150	-	-	5	
MOUNTAIN	76	69	1	9	14	7	968	467	-	1	2	
Mont. Idaho	3 7	4 6	- 1	1 1	1 -	- 1	21 165	24 45	-	-	-	
Wyo. Colo.	6 27	22	-	1	1	5	1 188	3 253	-	- 1	- 1	
N. Mex.	11	6	-	2	1	-	73	75	-	-	-	
Ariz. Utah	11 7	21 7	-	1	3 4	- 1	460 51	43 15	-	-	1 -	
Nev. PACIFIC	4 345	3 333	U	1 61	4 105	U 4	9 380	9 775	U	- 1	-	
Wash.	52	36	- -	1	4	4	94	227	-	-	12 7	
Oreg. Calif.	29 253	41 243	N -	N 29	N 75	-	33 222	83 418	-	-	5	
Alaska Hawaii	2 9	5 8	-	1 30	8 18	-	3 28	18 29	-	- 1	-	
Guam	-	-	U	-	11	U	-	3	U	-	1	
P.R. V.I.	3	7	Ŭ	-	-	U U	2	5	U U	-	-	
Amer. Samoa C.N.M.I.	U	U U	U U	U	U U	U U	U -	U U	U U	U -	U U	

TABLE III. (Cont'd) Provisional cases of selected notifiable diseases preventable by vaccination, United States, weeks ending August 18, 2001, and August 19, 2000 (33rd Week)

N: Not notifiable. U: Unavailable.

- : No reported cases.

	All Causes, By Age (Years)						P&I [†]		All Cau	ises, By	Age (Y	'ears)		P&I⁺	
Reporting Area	All Ages	≥65	45-64	25-44	1-24	<1	Total	Reporting Area	All Ages	≥65	45-64	25-44	1-24	<1	Total
NEW ENGLAND Boston, Mass. Bridgeport, Conn Cambridge, Mass Fall River, Mass. Hartford, Conn. Lowell, Mass. Lynn, Mass. New Bedford, Ma New Haven, Conn Providence, R.I. Somerville, Mass. Springfield, Mass Waterbury, Conn. Worcester, Mass. MID. ATLANTIC Albany, N.Y. Allentown, Pa. Buffalo, N.Y. Camden, N.J. Elizabeth, N.J. Elizabeth, N.J.	. 15 21 54 12 16 ss. 23 . 45 U 5 . 56	349 766 23 111 16 43 6 43 6 13 21 31 31 17 48 1,256 31 17 59 17 7 32	3 1 10 11 3 5 338 6 3 11 8	35 11 5 1 3 2 - 1 1 0 2 2 1 5 128 6 2 - 6 1 1	14 10 - 2 1 - - U - - - 1 23 1 - 2 1 - 2	13 8 1 - - 3 U 1 - 22 2 2 4 1 -	45 13 2 1 4 4 - 2 1 2 U - 8 3 5 7 2 4 7 2 - 2	S. ATLANTIC Atlanta, Ga. Baltimore, Md. Charlotte, N.C. Jacksonville, Fla Miami, Fla. Norfolk, Va. Richmond, Va. Savannah, Ga. St. Petersburg, I Tampa, Fla. Washington, De E.S. CENTRAL Birmingham, Al Chattanooga, Te Knoxville, Tenn Mobile, Ala. Montgomery, A	95 42 64 51 51a. 64 162 C. 100 I. 26 828 a. 177 mn. 65 95 . 185 40 40 41a. 54	710 91 95 78 73 61 26 37 36 48 96 58 58 11 537 122 61 106 61 26 26 360	290 56 33 28 24 21 9 16 12 7 5 24 15 182 35 11 15 24 49 6 82	99 22 16 9 9 4 3 6 - 5 13 12 - 64 11 7 3 4 17 4 7	40 6 2 2 6 7 3 3 - 1 5 5 - 25 7 - 3 5 4 3 3	28 22 2 3 6 6 2 1 1 2 3 3 3 3 1 1 - 20 2 3 8 2 3 8 2 2 3 2 3 2 3 2 3 2 3 2 3 2	75 2 13 15 9 11 1 4 2 4 11 3 - 67 12 4 5 8 16 1 8 2
Erie, Pa.§ Jersey City, N.J. New York City, N.Y. Newark, N.J. Paterson, N.J. Philadelphia, Pa. Pittsburgh, Pa.§ Reading, Pa. Rochester, N.Y. Schenectady, N.Y. Scranton, Pa.§ Syracuse, N.Y. Trenton, N.J. Utica, N.Y. Yonkers, N.Y.	50 7. 1,121 24 U 25 20 124	32 38 784 U 12 U 16 16 91 23 49 16 13 18	11	1 88 U 4 U - 1 9 3 1 3 - 1 1	2 13 U 2 U - - 1 - 1 - -	- 12 U 3 U - - - - - -	2 35 U 1 U 1 1 2 3 1 7 1 - 3	Nashville, Tenn. W.S. CENTRAL Austin, Tex. Baton Rouge, La Corpus Christi, Dallas, Tex. El Paso, Tex. Ft. Worth, Tex. Houston, Tex. Little Rock, Ark. New Orleans, La San Antonio, Te Shreveport, La. Tulsa, Okla.	Fex. 45 193 102 103 355 68 . 66	80 929 54 59 18 110 73 71 206 42 35 153 42 66	34 328 27 18 14 50 12 25 67 14 9 56 17 19	11 133 12 5 16 4 7 43 7 6 15 7 11	3 61 3 3 3 7 5 - 28 3 3 - 2 2 4	2 63 5 10 8 - 11 2 11 9 1 1	13 101 6 - 12 3 3 25 5 7 22 8 9
E.N. CENTRAL Akron, Ohio Canton, Ohio Chicago, III. Cincinnati, Ohio Cleveland, Ohio Dayton, Ohio Dayton, Ohio Detroit, Mich. Evansville, Ind. Fort Wayne, Ind. Grand Rapids, Mii Indianapolis, Ind. Lansing, Mich. Milwaukee, Wis. Peoria, III. Rockford, III. South Bend, Ind. Toledo, Ohio Youngstown, Ohi W.N. CENTRAL Des Moines, Iowa Duluth, Minn. Kansas City, Kans Kansas City, Kans Kansa, Nebr.	198 40 111 38 47 54 84 0 59 724 38 15 30 22	$\begin{array}{c} 978\\ 978\\ 29\\ 26\\ 0\\ 131\\ 103\\ 0\\ 9\\ 24\\ 126\\ 30\\ 81\\ 339\\ 0\\ 46\\ 513\\ 29\\ 12\\ 21\\ 16\\ 163\\ 566\\ 77\\ 162\\ 666\\ 77\\ 162\\ 163\\ 163\\ 163\\ 163\\ 163\\ 163\\ 163\\ 163$	U 6 8 5 10 39 9 18 3 7 9 17 1 127 7 1 9 10 5 28 17 11 127 1 9 10 5 28 17 19 18	81 3 2 U 4 6 12 6 U - 3 1 2 1 5 1 4 3 7 - 43 1 1 3 7 - 10 4 9 4 4	35 - U 5 2 4 7 U 1 2 - 2 6 - 4 - 1 1 1 - 28 1 1 5 6 9 - 6 9 - 6	32 3 1 U 1 3 3 1 U 2 1 1 1 1 6 - 3 - 2 2 - 2 13 1 1 1 - 1 - 3 1 2 3 1	67 1 3 U 4 · 4 7 U 1 4 1 3 14 6 6 2 3 3 5 · 8 3 1 2 6 1 8 7 7 4 9	MOUNTAIN Albuquerque, N Boise, Idaho Colo. Springs, C Denver, Colo. Las Vegas, Nev. Ogden, Utah Phoenix, Ariz. Pueblo, Colo. Salt Lake City, U Tucson, Ariz. PACIFIC Berkeley, Calif. Fresno, Calif. Glendale, Calif. Honolulu, Hawa Long Beach, Cali Gan Jogeles, Ca Pasadena, Calif. Portland, Oreg. Sacramento, Ca San Diego, Calif San Francisco, C San Jose, Calif. Santa Cruz, Cali Seattle, Wash. Tacoma, Wash. TOTAL	31 900. 59 97 203 30 157 23 tah 113 137 1,658 7 117 17 17 17 17 165 30 30 30 30 165 161 165 161 165 161 165 165 165 165	602 55 23 38 50 1366 23 94 16 80 87 1,170 4 79 252 252 19 114 138 20 19 114 138 20 78 44 67 7,044	180 12 9 26 4 24 5 17 34 293 27 9 12 61 10 28 35 U 3 31 5 17 2,106	87 9 - 8 125 3 18 1 12 9 114 - 8 3 2 2 7 18 131 9 U 16 3 10 6 7 7 84	35 2 2 1 5 5 - 12 - 3 5 49 1 3 1 - 3 9 - 8 5 2 U 4 - 7 - 6 3 10 3 10	23 - - - - - - - - - - - - -	50 3 1 1 5 2 12 11 1 1 5 2 12 11 1 5 2 12 11 1 5 2 12 11 1 5 2 12 11 1 5 2 12 11 1 5 2 12 11 1 5 2 12 11 5 2 12 11 5 2 12 11 5 2 12 11 5 2 12 11 5 2 12 11 5 2 12 11 5 2 12 11 5 2 12 11 5 2 12 11 5 2 12 11 5 2 12 11 1 5 2 12 11 1 5 2 12 11 1 5 2 12 11 1 5 2 12 11 1 5 2 12 11 1 5 2 12 11 1 5 2 12 11 1 5 2 12 11 1 5 2 12 11 1 5 2 12 11 1 5 2 12 11 1 5 2 12 11 1 5 2 12 11 1 5 2 12 11 1 5 2 12 11 1 5 2 12 11 1 5 2 12 11 1 5 2 11 1 1 5 2 11 1 1 5 2 11 1 1 5 2 11 1 1 5 2 11 1 1 5 2 11 1 1 5 2 11 1 1 5 2 11 1 1 1

TABLE IV. Deaths in 122 U.S. cities,* week ending August 18, 2001 (33rd Week)

U: Unavailable. -:No reported cases. *Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of ≥100,000. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included. ¹ Pneumonia and influenza. ⁸ Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks. ⁹ Total includes unknown ages.

	Total resident population			Bo	otulism			
Area	(in thousands)	AIDS*	Anthrax	Foodborne	Infant	Other [†]	Brucellosis	Chancroid [§]
United States	272,692	40,758 ¹	1	23	93	22	87	78
New England	13,496	2,028	_	_	1	_	2	2
Maine	1,253	40	_	_	1	_	_	_
N.H.	1,201	31	_	_	_	—	1	_
Vt.	594	38	—	—	—	—	1	2
Mass. R.I.	6,175 991	1,197 102	_	_	_	_		
Conn.	3,282	620	_	_	_	_		_
Mid. Atlantic	38,334	9,825	_	8	22	1	2	26
Upstate N.Y.	10,829	1,212	_	1	2	—	_	
N.Y. City	7,368	4,992	—	_	1	—	_	26
N.J. Pa.	8,143 11,994	1,929 1,692	_	6 1	10 9	1	2	_
E.N. Central	44,442	3,734	_	4	ž	1	9	3
Ohio	11,257	599	_	4	5	_	1	1
Ind.	5,943	389	—	_	_	—	_	—
III.	12,128	1,761	—	—	2	—	8	—
Mich.	9,864	767	—	_	—	1	_	
Wis. W.N. Central	5,250 18,800	218 956	1	1	1	_	8	2
Minn.	4,776	185	<u> </u>	1	_	_	2	_
lowa	2,869	94	_		NN	_	_	_
Mo.	5,468	459	_	_	—	—	5	_
N. Dak.	634	3	1	_	_	—		_
S. Dak. Nebr.	733	8	—	_	1	—	_	—
Kans.	1,666 2,654	79 128	_	_	_	_	1	_
S. Atlantic	49,561	11,234	_	_	3	1	13	17
Del.	754	221	_	_	_	_	_	_
Md.	5,172	1,465	_	_	1	—		_
D.C.	519	875	_	_	_	—	_	_
Va. W. Va.	6,873 1,807	891 63	_	_	_2	_	1	_2
N.C.	7,651	696	_	_	_	1	3	5
S.C.	3,886	810	_	_	_	_	_	10
Ga.	7,788	1,237	_	_	_	—	3	_
Fla.	15,111	4,976	—	—	5	_	6	_
E.S. Central	16,584 3,961	1,989 212	_	—	5 2	—	—	1
Ky. Tenn.	5,484	863	_	_	2	_	_	_
Ala.	4,370	483	_	_	1	_	_	1
Miss.	2,769	431	—	_	_	—	_	_
W.S. Central	30,325	3,892	—	2	9	1	25	25
Ark.	2,551	194	—	2	1	—	2	_
La. Okla.	4,372 3,358	679 352	_	—	_	_	1	6
Tex.	20,044	2,667	_	_	8	1	22	19
Mountain	17,128	1,403	_	_	15	_	5	1
Mont.	883	16	_	_	2	_	_	_
Idaho	1,252	22	_	_	_	—	_	_
Wyo.	480	11	—	_	_	—	1	1
Colo. N. Mex.	4,056 1,740	313 144	_	_	2	_	1	_
Ariz.	4,778	460	_	_	1	_	1	_
Utah	2,130	151	—	_	8	_	2	_
Nev.	1,809	286	—	_	2	-	_	_
Pacific	44,022	5,599	—	8	30	18	23	3
Wash. Oreg.	5,756 3,316	515 210	_	5	1	_	3	
Calif.	33,145	4,737	_	3	27	18	19	3
Alaska	620	22	_	_	_		_	_
Hawaii	1,185	115			2	_	1	_
Guam	149	15	_	_	_	_	_	_
P.R.	3,890	1,349						3 1
V.I. American Samoa	118	34	NA	NN	NN	NA	NN	1
American Samoa C.N.M.I.	62 67	_	NA	NA	NA	NA	NA	NA NA
0.11.101.1	0/	_	N/A	NA	NA.		NA	N/A

TABLE. Reported cases of notifiable diseases	, by geographic division and area —
United States, 2000	

 C.N.M.I.
 6/
 —
 NA
 NA

						Ehrlich	iosis
Area	Chlamydia*	Cholera	Cryptosporidiosis	Cyclosporiasis	Diphtheria	Human granulocytic	Human monocytic
United States	702,093	5	3,128	60	1	351	200
New England	24,333	_	143	10	_	168	3
Maine	1,474	_	20	—	—	1	_
N.H.	1,130	—	25		—		1
Vt.	526		28 37	NN 8	—	NN 30	NN 1
Mass. R.I.	10,967 2,632	_	4	NŇ	_	30 26	1
Conn.	7,604	_	29	2	_	111	
Mid. Atlantic	68,783	1	393	16	—	95	20
Upstate N.Y.	5,324	1	139	NN	_	85	12
N.Y. City	26,170	_	171	16	_		1
N.J. Pa.	10,814 26,475	_	19 64	NN	_	1 9	7
E.N. Central	120,846	_	983	4	_		_
Ohio	31,190	_	260	1	_	_	_
Ind.	14,063	_	72	1	—	—	_
III.	32,991	—	126	—	—	NN	NN
Mich. Wis.	26,237 16,365	_	97 428	2	_	_	_
WIS. W.N. Central	40,127	1	420 422	1	_	86	64
Minn.	8,102	1	190	1	_	79	4
lowa	5,987		77	_	_		_
Mo.	13,448	_	31	—	—	7	60
N. Dak.	909	—	18	NN	—	NN	NN
S. Dak. Nebr.	1,834	_	15 82	_	_	—	—
Kans.	3,791 6,056	_	9	NN	_	_	_
S. Atlantic	132,774	_	52 4	22	_	2	27
Del.	2,856	_	9	_	_	_	1
Md.	14,533	_	14	NN	_	NN	NN
D.C.	3,205	—	18	1	_	NN	NN
Va. W.Va.	15,352 2,144		21 3	_	_	—	
N.C.	21,985	_	28	_	_	2	11
S.C.	9,950	_		1	_	_	_
Ga.	29,359	_	191	11	—	—	5
Fla.	33,390	_	240	9	—	_	10
E.S. Central	51,152 8,063	_	51 7	 NN	_	—	52 3
Ky. Tenn.	15,069	_	12		_	_	47
Ala.	15,323	_	16	NN	_		2
Miss.	12,697	_	16	_	_	_	_
W.S. Central	102,210	3	175	2	_	—	34
Ark.	6,219	_	16	NN	—		22
La. Okla.	17,846 9,331	3	14 30	NN	_	NN	NN 12
Tex.	68,814	_	115	2	_	_	12
Mountain	40,187	_	182	5	_	_	_
Mont.	1,469	_	10	_	_	NN	NN
ldaho	1,907	—	28	NN	—	NN	NN
Wyo.	807	_	5		_		
Colo. N. Mex.	12,000 5,204	_	72 25	5	_	NN NN	NN NN
Ariz.	12,591	_	10	_	_		
Utah	2,190	_	28	_	_	_	_
Nev.	4,019	—	4	_		NN	NN
Pacific	121,681	—	255	_	1	—	—
Wash. Oreg	13,066 7,107	_	NN 20		_	NN	NN
Oreg. Calif.	95,392	_	20 235	NN	1		
Alaska	2,569	_			_	NN	NN
Hawaii	3,547	_	_	_	_	NN	NN
Guam	525	4	_	_	_	_	_
P.R.	2,695	_	_	_	_	_	_
V.I.	131	NA	NA	NA	NA	NA	NA
American Samo							
C.N.M.I.	NA	NA	NA	NA	NA	NA	NA

TABLE. (*Continued*) Reported cases of notifiable diseases, by geographic division and area — United States, 2000

NA: Not available. NN: Not notifiable. —: No reported cases. *Totals reported to the Division of Sexually Transmitted Diseases Prevention, NCHSTP, as of May 4, 2001. Chlamydia refers to genital infections caused by *C. trachomatis*.

	E	ncephalitis	*					
	California serogroup	Eastern		Escherichia	<i>coli</i> O157:H7		Haemophilus influenzae,	Hansen disease
Area	viral	equine	St. Louis	NETSS[†]	PHLIS [§]	Gonorrhea [¶]	invasive disease	(leprosy)
United States	114	3	2	4,528	3,625	358,995	1,398	91
New England Maine	_	1	_	380 32	383 30	6,883 90	132 2	_
N.H.	_	_	_	32 40	39	110	14	_
Vt.	_	_	_	37	37	65	10	NN
Mass.	_	1	_	167	175	3,045	46	_
R.I.	—		—	20	18	661	9	_
Conn.	_		_	84	84	2,912	51	_
Mid. Atlantic	1	_	_	443	348	40,953	243	6
Upstate N.Y. N.Y. City	_		_	303 23	82 18	8,445 11,669	109 65	NN 4
N.J.	_	_	_	117	119	7,232	41	4
Pa.	1	_	_	ŇŇ	129	13,607	28	1
E.N. Central	29	_	_	1,103	755	71,694	186	4
Ohio	18	_	_	275	226	19,303	55	2
Ind.	2	_	_	131	88	6,525	33	
III.	3		—	194	158	20,671	62	1
Mich.	6		—	141	104 179	18,182	11 25	1
Wis. W.N. Central	12	_	_	362 683	625	7,013 18,114	25 86	4
Minn.	8	_	_	212	232	3,160	80 51	- 4
lowa	4	_	_	180	148	1,392		2
Mo.	_		_	111	98	8,883	23	1
N. Dak.	—		—	23	21	73	4	NN
S. Dak.	—	_	_	56	59	277	1	
Nebr.	—	_	_	71	49	1,534	3	1
Kans.	40	2	—	30	18	2,795	4	4
S. Atlantic Del.	49	2	_	387 3	295 1	94,350 1,735	333	4
Md.	_	_	_	35	2	9,837	81	_
D.C.	_		_	1	NĀ	2,706		
Va.	_	_	_	77	68	10,175	41	_
W. Va.	40	_	_	15	13	645	15	—
N.C.	7	2	_	93	75	17,823	23	_
S.C.	2		—	21 44	17 40	8,383	7 85	NN
Ga. Fla.		_	_	44 98	40 79	20,265 22,781	81	4
E.S. Central	21	_	_	151	119	36,658	54	1
Ky.	2		_	40	33	3,502	12	_
Ténn.	19	_	_	62	55	11,876	26	1
Ala.	—	_	_	10	9	12,063	14	—
Miss.	—		_	39	22	9,217	2	
W.S. Central Ark.	_		2	227 56	287 38	54,035 3,642	68 2	19 1
La.	_	_	_	15		13,245	16	2
Okla.	_	_	_	19	34 17	4,229	46	
Tex.	_	_	2	137	178	32,919	4	16
Mountain	1	_	_	424	306	10,389	135	2
Mont.	—	—	—	31	NA	60	1	
Idaho	—	—	_	73	41	98	4	1
Wyo. Colo.	1	_	_	21 156	11 110	53 3,112	1 33	NN
N. Mex.		_	_	22	18	1,152	33 26	
Ariz.	_		_	56	45	4,130	53	
Utah	_	_	_	50	71	231	11	_
Nev.	—	—	_	15	10	1,553	6	1
Pacific	1		—	730	507	25,919	161	51
Wash.	NN	NN	_	237	206	2,418	9	1
Oreg. Calif.	1	_	_	134 313	115 169	1,038 21,619	34 48	2 33
Alaska	NN	NN	NN	313	6	361	48 45	_
Hawaii			_	14	11	483	25	15
Guam		_	_		NA	62	3	3
P.R.	_	_	_	7	NA	527	4	2
V.I.	NA	NA	NA	NÁ	NA	24	NĂ	NÁ
American Samo	oa —	_	—	—	NA	NA	—	1
C.N.M.I.	NA	NA	NA	NN	NA	NA	NA	NA

TABLE. (*Continued*) Reported cases of notifiable diseases, by geographic division and area — United States, 2000

NA: Not available. NN: Not notifiable. —: No reported cases. *No cases of Western equine encephalitis were reported in 2000. *National Electronic Telecommunications System for Surveillance. * Public Health Laboratory Information System. Totals reported to the National Center for Infectious Diseases as of May 25, 2001. * Totals reported to the Division of Sexually Transmitted Diseases Prevention, NCHSTP, as of May 4, 2001.

	Hantavirus	Hemolytic uremic	ŀ	lepatitis				
Area	pulmonary syndrome	syndrome, postdiarrheal	А	В	C; non-A, non-B	Legionellosis	Listeriosis	Lyme disease
United States	41	249	13,397	8,036	3,197	1,127	755	17,730
New England	1	33	399	140	36	56	59	5,801
Maine N.H.	_	3	22 19	5 19	2 NN	2 4	2 4	71 84
Vt.	1	1	10	6	5	5	3	40
Mass.		13	139	15	22	18	30	1,158
R.I.	_	16	31	46	7	9	2	675
Conn. Mid. Atlantic	_	16 36	178 1,527	49 1,165	NA 652	18 306	18 192	3,773 9,131
Upstate N.Y.	NN	26	265	154	46	100	87	4,152
N.Y. City	_	3	528	556		47	50	177
N.J.	NN	7	288	179	561	23	27	2,459
Pa. E.N. Central		24	446 1,691	276 832	45 235	136 292	28 136	2,343 773
Ohio	_	24 14	267	032 107	12	121	59	61
Ind.	_		132	84	12	41	9	23
III.	NN	NN	696	170	21	33	20	35
Mich.			491	427	202	53	33	23
Wis. W.N. Central	4	10 15	105 666	44 321	637	44 69	15 16	631 570
Minn.	4	13	185	58	15	16	7	465
lowa	_		67	38	2	15	2	405
Mo.	_	1	258	149	605	26	5	47
N. Dak.	2	_	4	3	1	1	2	2
S. Dak.	1		3	2		2	—	_
Nebr. Kans.	NN 1	NN 1	38 111	44 27	5 9	5 4	_	5 17
S. Atlantic	_	35	1,771	1,630	128	211	106	1,176
Del.	_	_	. 15	15	2	10	NN	167
Md.	NN	NN	210	131	16	70	22	688
D.C.	_	_	40	35	3	7	_	11
Va. W. Va.	—	3	164 56	174 30	3 23	37 NN	9 5	149 35
N.C.	NN	2	154	256	23	16	NŇ	47
S.C.	_	_	97	23	3	7	9	25
Ga.		10	376	350	4	10	21	
Fla. E.S. Central		20 12	659 418	616 501	54 466	54 45	40 22	54 50
Ky.	_	NN	418 63	81	400	40	4	50 13
Tenn.	_	12	156	239	112	15	14	28
Ala.	NN		56	71	10	5	4	6
Miss.	NN		143	110	304	3		3
W.S. Central	2	24	2,460	1,503	755	27	34	93
Ark. La.	_	2	144 107	109 157	12 456	7	1	7 8
Okla.	_	1	272	178	450	5	8	1
Tex.	2	21	1,937	1,059	271	15	25	77
Mountain	26	15	977	580	97	47	43	16
Mont.	_		7	8	5	2	_	_
ldaho Wyo.		NN 1	45 4	10 3	3 2	5	1	4 3
Colo.	8	12	223	108	18	15	11	
N. Mex.	10	_	70	144	16	1	2	_
Ariz.	4	NN	467	215	22	11	20	2
Utah	4	2	71 90	37	13	12	4 5	3
Nev. Pacific	8	55	90 3,488	55 1,364	18 191	1 74	147	4 120
Wash.	_	NN	298	132	44	19	12	9
Oreg.	NN	8	172	124	27	NN	6	13
Calif.	8	47	2,992	1,083	118	54	125	96
Alaska	NN	NN	13	13	NA	1	NN 4	2 NN
Hawaii	_		13	12	2			NN
Guam	 NINI		1	10	3		—	_
P.R. V.I.	NN NA	NN	255 NA	313 NA	1 NA	1 NA	NA	NA
American Samoa	NA a —	NA 	1	NA	NA	NA 		INA
C.N.M.I.	NA	NA	NÁ	NA	NA	NA	NA	NA
	NINI, NI							

TABLE. (Continued) Reported ca	ses of notifiable	diseases, by	geographic
division and area — United States,		•	

NA: Not available.

NN: Not notifiable. —: No reported cases.

		Meas		Meningo- coccal				
Area	Malaria	Indigenous	Imported [†]	disease	Mumps	Pertussis	Plague	Psittacosis
United States	1,560	60	26	2,256	338	7,867	6	17
New England	79	2	4	123	5	1,952	—	_
Maine N.H.	7 1	2	1	9 12	—	46 159	_	_
Vt.	4		3	4	_	254	_	_
Mass.	32	_	_	70	1	1,411	_	_
R.I.	13	_	_	9	1	28	—	
Conn.	22		_	19	3	54	_	NN
Mid. Atlantic Upstate N.Y.	392 80	15 9	9 1	262 79	31 12	819 385	_	3 3
N.Y. City	228	6	7	79 46	8	90	_	
N.J.	49	_	_	54	4	56	_	_
Pa.	35	_	1	83	7	288	_	—
E.N. Central	155	9	1	403	27	942	—	2
Ohio	23	3	—	94	9	389	—	1
Ind. III.	11 68	3	_	59 91	2 6	153 133	_	1
Mich.	34	3	_	115	7	127	_	_
Wis.	19	_	1	44	3	140	_	_
W.N. Central	84	1	2	157	26	829	—	2
Minn.	42	_	1	23	7	575	—	2
lowa	2	_	_	37	8	67 97	—	_
Mo. N. Dak.	21 3	_	_	67 3	5 1	9/	_	NN
S. Dak.	1	_	_	6	_	11	_	
Nebr.	8	_	_	9	2	28	_	_
Kans.	7	1	1	12	_3	42	—	_
S. Atlantic	382	4	_	337	50	593	—	5
Del. Md.	5 126	_	_	1 28	9	9 133		_
D.C.	120	_	_	20	9	3	_	_
Va.	55	2	_	42	11	134	_	_
W. Va.	4	_	_	15	1	3	_	—
N.C.	36	—	—	39	9	129		1
S.C. Ga.	2 47	_	_	26 53	11 2	63 52	_	_
Fla.	90	2	_	133	7	67	_	4
E.S. Central	48	_	_	137	7	132	_	1
Ky.	18	_	—	26	1	63	—	1
Tenn.	13	_	_	59	2	45		—
Ala. Miss.	16 1	—	_	36 16	4	20 4	NN	_
WISS. W.S. Central	73	1	_	245	38	452	_	_
Ark.	3	1	_	19	3	44	_	_
La.	14	_	_	46	5	21	_	_
Okla.	10	_	—	34	3	60	—	
Tex.	46	10	_	146	27	327		NN
Mountain Mont.	60 1	12	_	106 6	24 1	887 35	5	_
ldaho	5	_	_	7	1	53 64	_	_
Wyo.	_	_	_	2	1	4	1	_
Colo.	30	2	_	35	1	488	1	_
N. Mex.		_	_	11	1	91	1	_
Ariz. Utah	11 6	3	_	33 7	6 7	143 47	1 1	_
Nev.	7	3 7	_	5	6	47 15	_	_
Pacific	287	16	10	486	130	1,261	1	4
Wash.	43	2	1	71	10	458	_	1
Oreg.	40	13	_	70	NN	110	_	3
Calif.	194		6	328	89 8	631	1	—
Alaska Hawaii	10	1	3	9 8	23	21 41	_	_
Guam	2				16	4		
P.R.	2 5	3		10	2	12	_	_
V.I.	NĂ	NĂ	NA	NA	NÁ	NA	NA	NA
American Samoa	_	NA	NA	4	NA	_	_	NA
C.N.M.I.	NA	NA	NA	NA	NA	NA	NA	NA

TABLE. (*Continued*) Reported cases of notifiable diseases,* by geographic division and area — United States, 2000

NA: Not available. NN: Not notifiable. —: No reported cases. *No cases of paralytic poliomyelitis were reported in 2000. † Imported cases include only those resulting from importation from other countries.

		_			Ru	ubella	Salmo	onellosis
Area	QFever	Ral Animal	bies Human	RMSF*	Rubella	Congenital syndrome	NETSS[†]	PHLIS
United States	21	6,934	4	495	176	9	39,574	32,021
New England		829	-	435	12	-	2,191	2,215
Maine	_	139	_	2	12	—	127	104
N.H.	_	23	_	_	2	_	148	149
Vt.	NN	57	_	_		NN	140	143
Mass.	NN	277	_	2	8	_	1,236	1,252
R.I.	NN	60	_	_	1	_	152	158
Conn.	—	273	_	_	1	—	418	448
Mid. Atlantic	_	1,294	1	46	11	4	5,045	5,270
Upstate N.Y.	NN	823	1	7	1	1	1,293	1,282
N.Y. City	—	18	—	2	9	3	1,197	1,281
N.J.	NN	195 258	_	12 25	1	—	1,138	1,028
Pa. E.N. Central		258 169	_	25 31	1	_	1,417 5,451	1,679 3,706
Ohio	NN	52	_	18	•	—	1,602	1,459
Ind.		52 14	_	4	_	_	678	615
III.	NN	22	_	5	1	_	1,502	303
Mich.		69	_	4	_	_	904	942
Wis.	_	12	_	_	_	_	765	387
W.N. Central	3	542	1	54	2	—	2,483	2,516
Minn.	1	98	1	_	1	_	614	679
lowa	NN	81	—	2	—	—	373	351
Mo.	_	50	—	41	_	_	713	864
N. Dak.	_	117	_	_	_	—	73	78
S. Dak.	1	96	_	2		_	100	104
Nebr. Kans.	1	3 97	_	6 3	1	_	231 379	139 301
S. Atlantic	<u> </u>	2,402	1	189	119	4	8,629	5,922
Del.	NN	49	_	105	1	_	125	134
Md.	NN	413	_	19	_	_	804	733
D.C.			_		_	_	64	NA
Va.	NN	574	_	7	_	_	1,020	935
W. Va.	_	114	_	3	_	_	181	152
N.C.	—	571	_	78	89	—	1,149	1,138
S.C.	—	163	_	51	27	3	781	575
Ga.	—	357	1	19	_	_	1,689	1,726
Fla. E.S. Central	_	161 210	_	12 88	2 6	1	2,816 2,483	529 1,834
	_	210	—	60 4	1	—	393	269
Ky. Tenn.	_	107	_	4 58	1	—	709	821
Ala.	_	81	_	14	4	_	676	607
Miss.	NN	1	_	12	-	_	705	137
W.S. Central	_	880	_	69	10	_	4,952	3,025
Ark.	NN	32	_	24	3	_	729	578
La.	_	4	_	2	1	_	877	755
Okla.	NN	58	_	37	—	—	405	304
Tex.	NN	786	—	6	6	—	2,941	1,388
Mountain	6	294	—	13	2	—	2,786	2,496
Mont.	_	65	—	4	—	—	97	NA
Idaho	1	10	—	1	_	—	132	118
Wyo. Colo.	3	78	_	3	1	—	76 692	60 679
N. Mex.	3	21	_	1	_	_	239	208
Ariz.		101		_	1	_	798	208
Utah	1	10	_	2	<u> </u>	_	487	479
Nev.	1	9	_	2	_	_	265	182
Pacific	12	314	1	3	13	1	5,554	5,037
Wash.	_	_	_	2	7	_	659	677
Oreg.	4	7	_	2	—	_	297	362
Calif.	8	272	1	1	6	1	4,300	3,715
Alaska	NN	35	—	NN		NN	61	36
Hawaii	_	_	_	NN	_	_	237	247
Guam	_	_		—	1	_	28	NA
P.R.	NN	80	_		_	_	742	NA
V.I.	NA	NA	NA	NA	NA	NA	NA	NA
American Samo	a —						2	NA
C.N.M.I.	NA	NA	NA	NA	NA	NA	NA	NA

TABLE. (*Continued*) Reported cases of notifiable diseases, by geographic division and area — United States, 2000

NA: Not available. NN: Not notifiable. —: No reported cases. *Rocky Mountain spotted fever. * National Electronic Telecommunications System for Surveillance. * Public Health Laboratory Information System. Totals reported to the National Center for Infectious Diseases as of April 9, 2001.

			Streptococcal	Streptococcus	Streptococcal		Syphilis	
A	Shige NETSS*	ellosis PHLIS [†]	disease, invasive,	pneumoniae,	toxic-shock	All	Congenital	
Area	INE I 55°	PHLIS	group A	drug resistant	syndrome	stages [¶]	(age <1 yr)	secondary
United States	22,922	12,732	3,144	4,533	83	31,575	529	5,979
New England	409	385	229	143	2	662	1	91
Maine N.H.	11 7	11 8	12 16	NN	1	7 19	—	1 2
Vt.	4	_	16	16	1	19	_	
Mass.	283	262	47	NŇ		447	_	68
R.I.	35	34	15			38	_	4
Conn.	69	70	125 548	127 228	NN 8	151	1 69	16 280
Mid. Atlantic Upstate N.Y.	2,879 859	1,726 212	300	226	NA NA	4,431 234	6	280 15
N.Y. City	939	628	136	NA		2,711	32	117
N.J.	508	440	69	_	6	801	22	71
Pa.	573	446	_43	2	_2	685	_9	77
E.N. Central	4,215	1,334	792	223	53	3,843	75	1,210
Ohio Ind.	437 1,591	332 157	255 36	223	31 2	282 747	5	69 351
III.	1,188	179	204	NN NN	20	1.646	50	412
Mich.	667	610	267	NN	_	984	16	330
Wis.	332	56	30	NN	_	184	4	48
W.N. Central	2,627	2,064	258	500	8	507	5	64
Minn.	901	926	148	453	—	77	—	16
lowa Mo.	569 671	350 466	 63	NN 2	1	55 299	3	11 29
N. Dak.	61	52	9	24	_	200	_	
S. Dak.	8	6	16	8	2	1	_	_
Nebr.	162	117	5		1	.7	_	2
Kans.	255	147	17	13	4	67	2	6
S. Atlantic Del.	3,196 25	1,171 23	502 1	2,224 5	6	9,033 45	124	2,002 9
Md.	202	115	NN	NŇ	NN	1,172	16	300
D.C.	80	NA	18	69	NN	516	4	37
Va.	460	350	57	NN	NN	537	5	126
W. Va.	26	17	28	39	6	13		3
N.C. S.C.	400 144	271 94	88 13	NN 376	NN	1,494 853	18 24	483 229
Ga.	339	194	150	581	_	1,635	17	402
Fla.	1,520	107	147	1,154	_	2,768	40	413
E.S. Central	1,213	587	117	309	1	3,398	48	877
Ky.	530	121	30	32	_	253	3	_ 85
Tenn. Ala.	354 100	380 79	87 NN	277 NN	1	1,708 752	24 7	532 123
Miss.	229	73	NN		NN	685	, 14	123
W.S. Central	3,525	1,169	262	879	_	4,964	95	825
Ark.	235	63	5	14	_	367	16	104
La.	300	200	_	50	NN	973	7	209
Okla. Tex.	131 2,859	45 861	28 229	NN 815	NN	327 3,297	1 71	116 396
Mountain	2,009 1,295	868	399	26	5	1,135	26	225
Mont.	8	NA		_	NŇ			
Idaho	44	25	16	NN	2	11	_	1
Wyo.	5	3	8	11	_	5	_	1
Colo.	269	221	67 66	15	2	63 98	—	11 16
N. Mex. Ariz.	188 577	119 350	236	15	1	98 847	25	189
Utah	82	84	6	_	_	59	1	2
Nev.	122	66	_	—	—	52	_	5
Pacific	3,563	3,428	37	1	_	3,602	86	405
Wash.	501	414	NN	NN		171	—	66 12
Oreg. Calif.	164 2,853	113 2,865	NN NN	NN NN	NN NN	49 3,354	86	12 325
Alaska	2,003	2,005	NN	NN	NN	3,304		525
Hawaii	38	33	37	1	_	22	_	2
Guam	46	NA		_	_	9	_	1
P.R.	39	NA	_	_	_	1,339	16	175
V.I.	NA	NA	NA	—	NN	11	—	3
American Samo		NA				NA	NA	NA
C.N.M.I.	NA	NA	NA able —: No r	NA	NA	NA	NA	NA

TABLE. (Continued) Reported cases	of notifiable	diseases, b	y geographic
division and area — United States, 2000			

 C.N.M.I.
 NA
 NA

Area	Tetanus	Toxic- shock syndrome	Trichinosis	Tuberculosis [†]	Tularemia	Typhoid fever	Varicella ^s (chickenpox)
United States	35	135	16	16,377	142	377	27,382
New England	_	5	_	489	17	27	1,477
Maine	_	2	_	24	_	1	1,270
N.H.	—	_	_	22	_	_	NN
Vt.	_	1	—	4	NN		NN
Mass. R.I.		2	—	285	17	14 4	195
Conn.	_	NN	_	49 105	_	4 8	12 NN
Mid. Atlantic	6	25	_	2,692	_	111	
Upstate N.Y.	4	8	_	412	_	18	NN
N.Y. City	_	3	_	1,332	_	56	NN
N.J.	1	_	—	565	—	28	NN
Pa.	1	14	_	383		9	NN
E.N. Central	4	36	8	1,607	14	51	10,017
Ohio	—	3	1	340	1	8	1,192
Ind. III.	1	5 3	2	145 743	5 4	6 26	NN NA
Mich.	3	19	1	287	4	20	8,809
Wis.	_	6	4	92	3	2	16
W.N. Central	4	22	_	551	58	3	5,766
Minn.	2	6	_	178	2	1	NN
lowa	1	4	_	40	NN		NN
Mo.	_	3	_	211	28	1	5,744
N. Dak. S. Dak.	_	1	_	5 16	2 13	_	21 NN
S. Dak. Nebr.	_	6	_	24	2	_	1
Kans.	1	2	_	77	11	1	NN
S. Atlantic	4	8	2	3,327	5	56	2,786
Del.	_	1	_	28	2	_	NN
Md.	1	NN	1	282	—	9	NN
D.C.	_	_	_	85			_ 87
Va.	1	1	_	292 33	NN	22 1	592
W. Va. N.C.	_	5	_	33 447	2	3	2,024 NN
S.C.	_		_	286			83
Ga.	1	_	NN	703	1	9	NŇ
Fla.	1	1	1	1,171	—	12	NN
E.S. Central	3	8	—	1,013	4	3	123
<u>K</u> y.	1	2	NN	147	3	1	NN
Tenn.		4		383	1	2	123
Ala. Miss.	_2	2 NN	_	310 173	_	_	NN NN
W.S. Central	6	1	_	2,190	34	18	7,066
Ark.	1	_	NN	199	23	1	NN
La.	_	_	_	331	_		102
Okla.	_	1	_	154	11	1	NN
Tex.	5	NN	—	1,506	NN	16	6,964
Mountain	1	13	_	590	5	10	147
Mont.	1	5		21	—	2	NN
ldaho Wyo.	_		_	16 4	_	1	NN NN
Colo.	_	3	_	97	2	2	NN
N. Mex.	_	1	_	46	_	_	NN
Ariz.		_	_	261	1	4	NA
Utah	—	3	_	49	2	1	147
Nev.		1	_	96	_		NN
Pacific	1	17 NIN	6	3,918	5 2 2	98	
Wash. Oreg.	1	NN NN	_	258 119	2	6 6	NN NN
Calif.	6	17	_	3,297	1	78	NN
Alaska	_	NŇ	5	108		2	NN
Hawaii		NN	1	136	_	6	NN
Guam		_	_	54	_	_	297
P.R.	_	_	_	174	_	_	5,200
V.I.	NA	NA	NA	NA	NA	NA	NA
American Sam	noa —	<u> </u>	_	NA		1	104
C.N.M.I.	NA	NA	NA	75	NA	NA	NA

TABLE. (*Continued*) Reported cases of notifiable diseases,* by geographic division and area — United States, 2000

NA: Not available. NN: Not notifiable. -: No reported cases.

NAC AVAILABLE. — NN: NOT NOTIFIABLE. — NO reported cases.
 *No cases of yellow fever were reported in 2000.
 [†] Totals reported to the Division of Tuberculosis Elimination, NCHSTP, as of April 17, 2001.
 [§] Although not nationally notifiable, reporting is recommended by the Council for State and Territorial Epidemiologists.
 [§] Tennessee only reports cases that result in death to CDC.

Contributors to the Production of the MMWR (Weekly)

Weekly Notifiable Disease Morbidity Data and 122 Cities Mortality Data

Samuel L. Groseclose, D.V.M., M.P.H.

State Support Team Robert Fagan Jose Aponte Gerald Jones David Nitschke Scott Noldy Jim Vaughan Carol A. Worsham **CDC Operations Team** Carol M. Knowles Deborah A. Adams Willie J. Anderson Patsy A. Hall Mechele A. Hester Felicia J. Connor Pearl Sharp

Informatics

T. Demetri Vacalis, Ph.D.

Michele D. Renshaw

Erica R. Shaver

730

The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis for paper copy. To receive an electronic copy on Friday of each week, send an e-mail message to *listserv@listserv.cdc.gov*. The body content should read SUBscribe mmwr-toc. Electronic copy also is available from CDC's World-Wide Web server at http://www.cdc.gov/mmwr or from CDC's file transfer protocol server at ftp://ftp.cdc.gov/pub/Publications/mmwr. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone (202) 512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Address inquiries about the *MMWR* Series, including material to be considered for publication, to: Editor, *MMWR* Series, Mailstop C-08, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333; telephone (888) 232-3228.

All material in the *MMWR* Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Director, Centers for Disease Control and Prevention Jeffrey P. Koplan, M.D., M.P.H.	Director, Epidemiology Program Office Stephen B. Thacker, M.D., M.Sc.	Writers-Editors, <i>MMWR</i> (Weekly) Jill Crane David C. Johnson			
Deputy Director for Science and Public Health, Centers for Disease Control and Prevention David W. Fleming, M.D.	Editor, <i>MMWR</i> Series John W. Ward, M.D. Acting Managing Editor, <i>MMWR</i> (Weekly) Teresa F. Rutledge	Desktop Publishing Lynda G. Cupell Morie M. Higgins			
☆U.S. Government Printing Office: 2001-633-173/49005 Region IV					